Year |
Citation |
Score |
2024 |
Chi X, Yuan Y, Yu Z, Lin R. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal. Biometrische Zeitschrift. 66: e2300122. PMID 38368277 DOI: 10.1002/bimj.202300122 |
0.325 |
|
2024 |
Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical Trials (London, England). 17407745231207085. PMID 38243399 DOI: 10.1177/17407745231207085 |
0.309 |
|
2023 |
Zhao Y, Yuan Y, Korn EL, Freidlin B. Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38048044 DOI: 10.1158/1078-0432.CCR-23-2585 |
0.337 |
|
2023 |
Zhang W, Laird G, Chen J, Yuan Y. A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints. Statistics in Medicine. PMID 37937591 DOI: 10.1002/sim.9948 |
0.338 |
|
2023 |
Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37725573 DOI: 10.1158/1078-0432.CCR-23-2222 |
0.338 |
|
2022 |
Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. The Annals of Applied Statistics. 16: 2481-2504. PMID 36329718 DOI: 10.1214/22-aoas1600 |
0.323 |
|
2022 |
Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Statistics in Medicine. PMID 35098585 DOI: 10.1002/sim.9337 |
0.315 |
|
2021 |
Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis. 16: 179-202. PMID 34267857 DOI: 10.1214/20-ba1205 |
0.311 |
|
2021 |
Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemporary Clinical Trials. 106338. PMID 33711459 DOI: 10.1016/j.cct.2021.106338 |
0.314 |
|
2021 |
Shi H, Cao J, Yuan Y, Lin R. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Statistics in Medicine. PMID 33650708 DOI: 10.1002/sim.8922 |
0.317 |
|
2020 |
Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. British Journal of Cancer. PMID 32868897 DOI: 10.1038/S41416-020-01033-X |
0.342 |
|
2020 |
Abi Jaoude J, Kouzy R, Minsky BD, Fuller CD, Yuan Y, Do KA, Taniguchi CM, Ludmir EB. Sponsor-Involved Statistical Analyses in Phase III Cancer Clinical Trials. International Journal of Cancer. PMID 32621758 DOI: 10.1002/Ijc.33180 |
0.485 |
|
2020 |
Zhou H, Chen C, Sun L, Yuan Y. Bayesian optimal phase II clinical trial design with time-to-event endpoint. Pharmaceutical Statistics. PMID 32524679 DOI: 10.1002/Pst.2030 |
0.389 |
|
2020 |
Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharmaceutical Statistics. PMID 32248647 DOI: 10.1002/Pst.2013 |
0.654 |
|
2020 |
Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials. 105972. PMID 32151751 DOI: 10.1016/J.Cct.2020.105972 |
0.656 |
|
2020 |
Li Y, Yuan Y. PA-CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials. Biometrics. PMID 31950483 DOI: 10.1111/Biom.13217 |
0.366 |
|
2020 |
Lin R, Thall PF, Yuan Y. A Phase I–II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes Bayesian Analysis. DOI: 10.1214/20-Ba1205 |
0.366 |
|
2020 |
Gunn GB, Ferrarotto R, Johnson FM, Bell D, Cardoso R, Johnson JM, Rubin ML, Yuan Y, Frank SJ, Fuller CD, Rosenthal DI, Kupferman ME, Goepfert R, Hessel AC, Hutcheson KA, et al. Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study. Journal of Clinical Oncology. 38: 6578-6578. DOI: 10.1200/Jco.2020.38.15_Suppl.6578 |
0.403 |
|
2020 |
Majd N, Lin HY, Yuan Y, Alfaro-Munoz K, Hunter K, Heimberger AB, Groot JFD. Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab. Journal of Clinical Oncology. 38: 2559-2559. DOI: 10.1200/Jco.2020.38.15_Suppl.2559 |
0.347 |
|
2020 |
Yuan Y, Lin R, Li D, Nie L, Warren K. Abstract A21: Time-to-event Bayesian optimal interval design to accelerate phase I pediatric oncology trials Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A21 |
0.422 |
|
2020 |
Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials Statistics in Biopharmaceutical Research. 1-9. DOI: 10.1080/19466315.2020.1811147 |
0.39 |
|
2019 |
Zhou Y, Lee JJ, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Statistics in Medicine. PMID 31621952 DOI: 10.1002/Sim.8361 |
0.403 |
|
2019 |
Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clinical Trials (London, England). 1740774519871471. PMID 31450957 DOI: 10.1177/1740774519871471 |
0.346 |
|
2019 |
Lin R, Thall PF, Yuan Y. An Adaptive Trial Design to Optimize Dose--Schedule Regimes with Delayed Outcomes. Biometrics. PMID 31273750 DOI: 10.1111/Biom.13116 |
0.422 |
|
2019 |
Lin R, Yuan Y. On the relative efficiency of model-assisted designs: a conditional approach. Journal of Biopharmaceutical Statistics. 1-15. PMID 31258039 DOI: 10.1080/10543406.2019.1632881 |
0.401 |
|
2019 |
Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics (Oxford, England). PMID 30984972 DOI: 10.1093/Biostatistics/Kxz007 |
0.434 |
|
2019 |
Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. European Journal of Cancer (Oxford, England : 1990). 112: 83-93. PMID 30951926 DOI: 10.1016/J.Ejca.2019.02.007 |
0.344 |
|
2019 |
Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 30924863 DOI: 10.1093/Jnci/Djz049 |
0.38 |
|
2019 |
Wu J, Yuan Y, Cordova C, Aboud O, Penas-Prado M, Theeler BJ, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Siegel C, Antony R, Garren N, Lawhon T, et al. Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults. Journal of Clinical Oncology. 37: 2031-2031. DOI: 10.1200/Jco.2019.37.15_Suppl.2031 |
0.364 |
|
2019 |
Wages NA, Yuan Y. Preface to the themed issue on ‘Early phase clinical trial design methodology’ Journal of the Royal Statistical Society Series C-Applied Statistics. 68: 267-269. DOI: 10.1111/Rssc.12329 |
0.349 |
|
2019 |
Yust-Katz S, Donthireddy V, Mandel J, Abunafeesa H, Patil N, Yadav D, Jabbour-Aida H, Wu J, Yuan Y, Tsavachidis S, Walbert T, Bondy M, Armstrong T. QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA Neuro-Oncology. 21: vi204-vi204. DOI: 10.1093/Neuonc/Noz175.850 |
0.31 |
|
2019 |
Wu J, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Antony R, Garren N, Siegel C, Cordova C, Aboud O, Vera E, Lawhon T, Penas-Prado M, Theeler B, ... ... Yuan Y, et al. ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS Neuro-Oncology. 21: vi27-vi28. DOI: 10.1093/Neuonc/Noz175.104 |
0.353 |
|
2019 |
Gross N, Ferrarotto R, Nagarajan P, Bell D, El-Naggar A, Johnson J, Yuan Y, Glisson B, Wong M, Rosenthal D, Esmaeli B, Migden M, Wargo J, Weber R, Myers J. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN) Annals of Oncology. 30: v910. DOI: 10.1093/Annonc/Mdz394.071 |
0.317 |
|
2018 |
Liu S, Guo B, Yuan Y. A Bayesian Phase I/II Trial Design for Immunotherapy. Journal of the American Statistical Association. 113: 1016-1027. PMID 31741544 DOI: 10.1080/01621459.2017.1383260 |
0.425 |
|
2018 |
Tang R, Shen J, Yuan Y. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Statistics in Medicine. PMID 30419609 DOI: 10.1002/Sim.8026 |
0.352 |
|
2018 |
Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, et al. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology. 13: 19-23. PMID 30386824 DOI: 10.1016/J.Ctro.2018.08.003 |
0.505 |
|
2018 |
Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Designs-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 5483-5484. PMID 30385656 DOI: 10.1158/1078-0432.Ccr-18-2677 |
0.353 |
|
2018 |
Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, et al. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. Bmc Cancer. 18: 903. PMID 30231854 DOI: 10.1186/S12885-018-4808-5 |
0.426 |
|
2018 |
Guo B, Li D, Yuan Y. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. Pharmaceutical Statistics. PMID 29882388 DOI: 10.1002/Pst.1869 |
0.415 |
|
2018 |
Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, et al. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology. PMID 29788429 DOI: 10.1093/Neuonc/Noy056 |
0.314 |
|
2018 |
Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29769209 DOI: 10.1158/1078-0432.Ccr-18-0246 |
0.423 |
|
2018 |
Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine. PMID 29682777 DOI: 10.1002/Sim.7674 |
0.659 |
|
2018 |
Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29661774 DOI: 10.1158/1078-0432.Ccr-18-0168 |
0.438 |
|
2018 |
Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. Bmc Medical Research Methodology. 18: 32. PMID 29580203 DOI: 10.1186/S12874-018-0473-2 |
0.574 |
|
2018 |
Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials (London, England). 1740774518755122. PMID 29499621 DOI: 10.1177/1740774518755122 |
0.375 |
|
2018 |
Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL. A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics. PMID 29359314 DOI: 10.1111/Biom.12842 |
0.401 |
|
2018 |
Msaouel P, Thall PF, Yuan Y, Chen I, Tannir NM. A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps708 |
0.334 |
|
2018 |
Ursino M, Yuan Y, Alberti C, Comets E, Favrais G, Friede T, Lentz F, Stallard N, Zohar S. A dose finding design for seizure reduction in neonates Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 427-444. DOI: 10.1111/Rssc.12289 |
0.388 |
|
2018 |
Mu R, Yuan Y, Xu J, Mandrekar SJ, Yin J. gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 289-308. DOI: 10.1111/Rssc.12263 |
0.399 |
|
2018 |
Chu Y, Yuan Y. BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity Journal of the Royal Statistical Society Series C-Applied Statistics. 67: 723-740. DOI: 10.1111/Rssc.12255 |
0.361 |
|
2018 |
Armstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Gilbert M. RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB Neuro-Oncology. 20: vi241-vi241. DOI: 10.1093/Neuonc/Noy148.998 |
0.321 |
|
2018 |
Puduvalli V, Wu J, Yuan Y, Armstrong T, Wu J, Giglio P, Xu J, Colman H, Walbert T, Raizer J, Groves M, Iwamoto F, Tran D, Avgeropoulos N, Paleologos N, et al. ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Neuro-Oncology. 20: vi13-vi13. DOI: 10.1093/Neuonc/Noy148.047 |
0.315 |
|
2018 |
de Groot J, Penas-Prado M, Mandel J, O’Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse JT, Rao G, Weinberg J, Prabhu S, ... ... Yuan Y, et al. ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS Neuro-Oncology. 20: vi2-vi2. DOI: 10.1093/Neuonc/Noy148.004 |
0.326 |
|
2017 |
Guo B, Yuan Y. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Journal of the American Statistical Association. 112: 508-520. PMID 32863478 DOI: 10.1080/01621459.2016.1228534 |
0.372 |
|
2017 |
Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29267863 DOI: 10.1093/Annonc/Mdx795 |
0.376 |
|
2017 |
Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 66: 979-996. PMID 29249839 DOI: 10.1111/Rssc.12204 |
0.627 |
|
2017 |
Cai C, Rahbar MH, Hossain MM, Yuan Y, Gonzales NR. A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemporary Clinical Trials Communications. 7: 11-17. PMID 29062975 DOI: 10.1016/J.Conctc.2017.05.002 |
0.385 |
|
2017 |
Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, A Kent T, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-Oncology. PMID 29016865 DOI: 10.1093/Neuonc/Nox144 |
0.341 |
|
2017 |
Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. Journal of the American Statistical Association. 112: 11-23. PMID 28943681 DOI: 10.1080/01621459.2016.1176926 |
0.368 |
|
2017 |
Shen W, Ning J, Yuan Y, Lok AS, Feng Z. Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics. PMID 28742219 DOI: 10.1111/Biom.12750 |
0.302 |
|
2017 |
Ahn J, Morita S, Wang W, Yuan Y. Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. Statistical Methods in Medical Research. 962280217715051. PMID 28629259 DOI: 10.1177/0962280217715051 |
0.322 |
|
2017 |
Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Statistics in Medicine. PMID 28589563 DOI: 10.1002/Sim.7338 |
0.368 |
|
2017 |
Yan F, Mandrekar SJ, Yuan Y. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28546227 DOI: 10.1158/1078-0432.Ccr-17-0220 |
0.396 |
|
2017 |
Chen Z, Li Z, Zhuang R, Yuan Y, Kutner M, Owonikoko T, Curran WJ, Kowalski J. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile. Plos One. 12: e0170187. PMID 28125617 DOI: 10.1371/Journal.Pone.0170187 |
0.386 |
|
2017 |
Wu J, Bryla C, McCoy A, Lisa B, Garren N, Siegel C, Grajkowska E, Theeler B, Park DM, Parrott T, Armstrong TS, Yuan Y, Gilbert MR. ACTR-69. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR ADULTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA AND GLIOBLASTOMA Neuro-Oncology. 19: vi15-vi15. DOI: 10.1093/Neuonc/Nox168.056 |
0.346 |
|
2016 |
Zang Y, Yuan Y. Optimal sequential enrichment designs for phase II clinical trials. Statistics in Medicine. PMID 27640874 DOI: 10.1002/Sim.7128 |
0.379 |
|
2016 |
Zhang L, Yuan Y. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials. Statistics in Medicine. PMID 27580928 DOI: 10.1002/Sim.7095 |
0.413 |
|
2016 |
Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27407096 DOI: 10.1158/1078-0432.Ccr-16-0592 |
0.352 |
|
2016 |
Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine. PMID 27189672 DOI: 10.1002/Sim.6989 |
0.369 |
|
2016 |
Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Statistics in Medicine. PMID 27112322 DOI: 10.1002/Sim.6971 |
0.378 |
|
2016 |
Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Statistics in Medicine. PMID 27090197 DOI: 10.1002/Sim.6966 |
0.328 |
|
2016 |
Yuan Y, Liu Y, Li B, Wang B, Wang S, Peng Y. Short-chain fatty acids production and microbial community in sludge alkaline fermentation: Long-term effect of temperature. Bioresource Technology. 211: 685-690. PMID 27060243 DOI: 10.1016/J.Biortech.2016.03.138 |
0.423 |
|
2016 |
Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine. PMID 27027650 DOI: 10.1002/Sim.6933 |
0.623 |
|
2016 |
Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine. PMID 26991076 DOI: 10.1002/Sim.6941 |
0.657 |
|
2016 |
Riviere MK, Yuan Y, Jourdan JH, Dubois F, Zohar S. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research. PMID 26988926 DOI: 10.1177/0962280216631763 |
0.409 |
|
2016 |
Zang Y, Liu S, Yuan Y. Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics (Oxford, England). PMID 26951724 DOI: 10.1093/Biostatistics/Kxw006 |
0.343 |
|
2016 |
Guo B, Li Y, Yuan Y. A dose-schedule finding design for phase I-II clinical trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 65: 259-272. PMID 26877554 DOI: 10.1111/Rssc.12113 |
0.419 |
|
2016 |
Zhou R, Scheurer ME, Gilbert MR, Bondy M, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Brachman D, Bearden J, McGovern SL, Wilson SS, Judy KD, Robins HI, et al. Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Journal of Clinical Oncology. 34: 2049-2049. DOI: 10.1200/Jco.2016.34.15_Suppl.2049 |
0.316 |
|
2016 |
Zang Y, Lee JJ, Yuan Y. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification Journal of the Royal Statistical Society Series C-Applied Statistics. 65: 585-601. DOI: 10.1111/Rssc.12140 |
0.34 |
|
2016 |
Yuan X, Ji B, Yuan Y, Wu X, Zhang X. Co-scheduling of lock and water-land transshipment for ships passing the dam Applied Soft Computing Journal. 45: 150-162. DOI: 10.1016/j.asoc.2016.04.019 |
0.361 |
|
2015 |
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, et al. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology. PMID 26476729 DOI: 10.1007/S11060-015-1958-Z |
0.325 |
|
2015 |
Chen Z, Yuan Y, Li Z, Kutner M, Owonikoko T, Curran WJ, Khuri F, Kowalski J. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. Contemporary Clinical Trials. 43: 133-41. PMID 26012358 DOI: 10.1016/J.Cct.2015.05.014 |
0.455 |
|
2015 |
DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). Journal of Neuro-Oncology. 123: 85-91. PMID 25859842 DOI: 10.1007/S11060-015-1764-7 |
0.322 |
|
2015 |
Shen W, Ning J, Yuan Y. A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics. 71: 439-49. PMID 25758584 DOI: 10.1111/Biom.12293 |
0.344 |
|
2015 |
Shen W, Ning J, Yuan Y. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Statistics in Medicine. 34: 2104-15. PMID 25756852 DOI: 10.1002/Sim.6474 |
0.444 |
|
2015 |
Jin IH, Huo L, Yin G, Yuan Y. Phase I trial design for drug combinations with Bayesian model averaging. Pharmaceutical Statistics. 14: 108-19. PMID 25641851 DOI: 10.1002/Pst.1668 |
0.495 |
|
2015 |
Guo B, Yuan Y. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts. Statistics in Medicine. 34: 1721-32. PMID 25626676 DOI: 10.1002/Sim.6443 |
0.474 |
|
2015 |
Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine. 34: 1681-94. PMID 25626429 DOI: 10.1002/Sim.6442 |
0.645 |
|
2015 |
Guo B, Zang Y, Yuan Y. A Bayesian phase I/II clinical trial design in the presence of informative dropouts Statistics and Its Interface. 8: 217-226. DOI: 10.4310/Sii.2015.V8.N2.A9 |
0.344 |
|
2015 |
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Groves MD, Raizer JJ, Giglio P, Colman H, Peereboom DM, Walbert T, Avgeropoulos NG, Iwamoto FM, Chamberlain MC, Paleologos N, Fink KL, et al. Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). Journal of Clinical Oncology. 33: 2012-2012. DOI: 10.1200/Jco.2015.33.15_Suppl.2012 |
0.338 |
|
2015 |
Fellman BM, Yuan Y. Bayesian optimal interval design for phase I oncology clinical trials Stata Journal. 15: 110-120. DOI: 10.1177/1536867X1501500107 |
0.408 |
|
2015 |
Zang Y, Liu S, Yuan Y. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers Journal of the Royal Statistical Society. Series C: Applied Statistics. 64: 635-650. DOI: 10.1111/Rssc.12092 |
0.377 |
|
2015 |
Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 507-523. DOI: 10.1111/Rssc.12089 |
0.434 |
|
2015 |
Riviere M-, Yuan Y, Dubois F, Zohar S. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 215-229. DOI: 10.1111/Rssc.12072 |
0.422 |
|
2015 |
Zhou R, Scheurer M, Gilbert M, Bondy M, Sulman E, Yuan Y, Liu Y, Vera-Bolanos E, Wendland M, Brachman D, Bearden J, McGovern S, Wilson S, Judy K, Robins HI, et al. EPID-33RISK MODELING FOR VASCULAR TOXICITY IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v85.3-v85. DOI: 10.1093/Neuonc/Nov213.33 |
0.322 |
|
2015 |
Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera-Bolanos E, Wendland MM, Brachman DG, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, et al. EPID-25GERMLINE POLYMORPHISMS IN MGMT INCREASE ABILITY TO MODEL TEMOZOLOMIDE (TMZ)-RELATED MYELOTOXICITY RISK IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v83.3-v83. DOI: 10.1093/Neuonc/Nov213.25 |
0.323 |
|
2015 |
Wu J, Puduvalli VK, Yuan Y, Armstrong T, Walker B, Upshaw C, Giglio P, Colman H, Groves MD, Raizer J, Walbert T, Tran D, Avgeropoulos N, Iwamoto F, Peereboom D, et al. ATCT-34BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB PLUS VORINOSTAT VERSUS BEVACIZUMAB ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 17: v9.2-v9. DOI: 10.1093/Neuonc/Nov206.34 |
0.353 |
|
2014 |
Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. Journal of the American Statistical Association. 109: 525-536. PMID 25382884 DOI: 10.1080/01621459.2014.881740 |
0.404 |
|
2014 |
Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. Plos One. 9: e98147. PMID 24875783 DOI: 10.1371/Journal.Pone.0098147 |
0.627 |
|
2014 |
Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials (London, England). 11: 319-327. PMID 24844841 DOI: 10.1177/1740774514529848 |
0.433 |
|
2014 |
Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics. 13: 247-57. PMID 24828456 DOI: 10.1002/Pst.1621 |
0.473 |
|
2014 |
Cai C, Liu S, Yuan Y. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine. 33: 4017-28. PMID 24817556 DOI: 10.1002/Sim.6200 |
0.402 |
|
2014 |
Cai C, Yuan Y, Ji Y. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents. Journal of the Royal Statistical Society. Series C, Applied Statistics. 63: 159-173. PMID 24511160 DOI: 10.1111/Rssc.12039 |
0.379 |
|
2014 |
Armstrong TS, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. At-07A Phase Ii Study Of Lapatinib And Dose-Dense Temozolomide (Tmz) For Adults With Recurrent Ependymoma: Patient Reported Outcomes (Pro) From A Cern Clinical Trial. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.7 |
0.329 |
|
2014 |
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.23 |
0.366 |
|
2013 |
Liu S, Yin G, Yuan Y. BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. The Annals of Applied Statistics. 7: 1837-2457. PMID 24707327 DOI: 10.1214/13-Aoas661 |
0.475 |
|
2013 |
Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics. 69: 914-24. PMID 24328715 DOI: 10.1111/Biom.12100 |
0.333 |
|
2013 |
Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 119: 2747-53. PMID 23633392 DOI: 10.1002/Cncr.28031 |
0.36 |
|
2013 |
Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clinical Trials (London, England). 10: 353-62. PMID 23359875 DOI: 10.1177/1740774512470316 |
0.363 |
|
2012 |
Huo L, Yuan Y, Yin G. Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. Bayesian Analysis (Online). 7: 1035-1052. PMID 23956811 DOI: 10.1214/12-Ba735 |
0.391 |
|
2012 |
Zhang G, Yuan Y. BAYESIAN MODELING LONGITUDINAL DYADIC DATA WITH NONIGNORABLE DROPOUT, WITH APPLICATION TO A BREAST CANCER STUDY. The Annals of Applied Statistics. 6: 753-771. PMID 23814631 DOI: 10.1214/11-Aoas515 |
0.522 |
|
2011 |
Yuan Y, Yin G. BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. The Annals of Applied Statistics. 5: 924-942. PMID 22375162 DOI: 10.1214/10-Aoas433 |
0.416 |
|
2011 |
Yuan Y, Yin G. Robust EM Continual Reassessment Method in Oncology Dose Finding. Journal of the American Statistical Association. 106: 818-831. PMID 22375092 DOI: 10.1198/Jasa.2011.Ap09476 |
0.423 |
|
2011 |
Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Statistics in Medicine. 30: 1218-29. PMID 21432894 DOI: 10.1002/Sim.4218 |
0.375 |
|
2011 |
Yuan Y, Yin G. Bayesian hybrid dose-finding design in phase I oncology clinical trials. Statistics in Medicine. 30: 2098-108. PMID 21365672 DOI: 10.1002/Sim.4164 |
0.4 |
|
2011 |
Lei X, Yuan Y, Yin G. Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Analysis. 17: 156-74. PMID 20364321 DOI: 10.1007/S10985-010-9163-Z |
0.419 |
|
2010 |
Yuan Y, Yin G. Bayesian quantile regression for longitudinal studies with nonignorable missing data. Biometrics. 66: 105-14. PMID 19459836 DOI: 10.1111/J.1541-0420.2009.01269.X |
0.324 |
|
2009 |
Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics. 65: 866-75. PMID 18759848 DOI: 10.1111/J.1541-0420.2008.01119.X |
0.416 |
|
2009 |
Yuan Y, Little RJ. Mixed-effect hybrid models for longitudinal data with nonignorable dropout. Biometrics. 65: 478-86. PMID 18759842 DOI: 10.1111/J.1541-0420.2008.01102.X |
0.592 |
|
2009 |
Yuan Y, Little RJ. Meta-analysis of studies with missing data. Biometrics. 65: 487-96. PMID 18565168 DOI: 10.1111/J.1541-0420.2008.01068.X |
0.612 |
|
2009 |
Yin G, Yuan Y. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials Journal of the American Statistical Association. 104: 954-968. DOI: 10.1198/Jasa.2009.Ap08425 |
0.432 |
|
2009 |
Yuan Y, Yin G. Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes Journal of the Royal Statistical Society: Series C (Applied Statistics). 58: 719-736. DOI: 10.1111/J.1467-9876.2009.00674.X |
0.428 |
|
2009 |
Yin G, Yuan Y. Bayesian dose finding in oncology for drug combinations by copula regression Journal of the Royal Statistical Society: Series C (Applied Statistics). 58: 211-224. DOI: 10.1111/J.1467-9876.2009.00649.X |
0.402 |
|
2008 |
Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose finding. Statistics in Medicine. 27: 5664-78. PMID 18618901 DOI: 10.1002/Sim.3372 |
0.393 |
|
2007 |
Yuan Y, Little RJ. Parametric and semiparametric model-based estimates of the finite population mean for two-stage cluster samples with item nonresponse. Biometrics. 63: 1172-80. PMID 17489967 DOI: 10.1111/J.1541-0420.2007.00816.X |
0.59 |
|
Low-probability matches (unlikely to be authored by this person) |
2023 |
Thall PF, Zang Y, Yuan Y. Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical Statistics. PMID 37038957 DOI: 10.1002/pst.2301 |
0.3 |
|
2018 |
Murray TA, Yuan Y, Thall PF. A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. Journal of the American Statistical Association. 113: 1255-1267. PMID 30739965 DOI: 10.1080/01621459.2017.1340887 |
0.299 |
|
2014 |
Yuan Y, Mackinnon DP. Robust mediation analysis based on median regression. Psychological Methods. 19: 1-20. PMID 24079925 DOI: 10.1037/A0033820 |
0.298 |
|
2020 |
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, et al. A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma. Neuro-Oncology. PMID 32166308 DOI: 10.1093/Neuonc/Noaa062 |
0.298 |
|
2009 |
Song PX, Li M, Yuan Y. Joint regression analysis of correlated data using Gaussian copulas. Biometrics. 65: 60-8. PMID 18510653 DOI: 10.1111/J.1541-0420.2008.01058.X |
0.297 |
|
2020 |
Avila M, Wathoo C, Zeng J, Andersen C, Yuan Y, Yap TA, Ahnert JR, Meric-Bernstam F. Variety of clinical trial enrollment by actionable tumor suppressor genotype. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15674 |
0.297 |
|
2022 |
Zhou Y, Zhao Y, Cicconetti G, Mu Y, Yuan Y, Wang L, Penugonda S, Salman Z. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharmaceutical Statistics. PMID 36333972 DOI: 10.1002/pst.2272 |
0.297 |
|
2020 |
Theeler BJ, Jung J, Burton E, Gonzalez J, Leeper H, Wu J, Nduom E, Zaghloul K, Ray-Chaudhury A, Quezado M, Raffeld M, Allen JE, Prabhu VV, Stogniew M, Oster W, ... Yuan Y, et al. A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps2576 |
0.297 |
|
2021 |
Mu R, Xu J, Tang RS, Kopetz S, Yuan Y. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Statistics in Medicine. PMID 34730248 DOI: 10.1002/sim.9242 |
0.297 |
|
2009 |
Yuan Y, MacKinnon DP. Bayesian mediation analysis. Psychological Methods. 14: 301-22. PMID 19968395 DOI: 10.1037/A0016972 |
0.296 |
|
2015 |
Guo B, Yuan Y. A comparative review of methods for comparing means using partially paired data. Statistical Methods in Medical Research. PMID 25834090 DOI: 10.1177/0962280215577111 |
0.296 |
|
2011 |
Yuan Y, Yin G. Dose-response curve estimation: a semiparametric mixture approach. Biometrics. 67: 1543-54. PMID 21627631 DOI: 10.1111/J.1541-0420.2011.01620.X |
0.291 |
|
2022 |
Liu R, Yuan Y, Sen S, Yang X, Jiang Q, Li XN, Lu CC, Göneng M, Tian H, Zhou H, Lin R, Marchenko O. Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials. Statistics in Biopharmaceutical Research. 14: 270-282. PMID 37275462 DOI: 10.1080/19466315.2022.2081602 |
0.29 |
|
2012 |
Yuan Y, Johnson VE. Goodness-of-fit diagnostics for Bayesian hierarchical models. Biometrics. 68: 156-64. PMID 22050079 DOI: 10.1111/J.1541-0420.2011.01668.X |
0.29 |
|
2013 |
Ahn J, Yuan Y, Parmigiani G, Suraokar MB, Diao L, Wistuba II, Wang W. DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics (Oxford, England). 29: 1865-71. PMID 23712657 DOI: 10.1093/Bioinformatics/Btt301 |
0.289 |
|
2019 |
Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha P, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W. Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts. Cancer Research. PMID 31719101 DOI: 10.1158/0008-5472.Can-19-0728 |
0.289 |
|
2015 |
Zhu Z, Mok SC, Su X, Yuan Y, Lu KH. Abstract 1930: New technology of RNA profiling at single cell level leads to the discovery of tumor heterogeneity in grade 1 endometrial cancer Cancer Research. 75: 1930-1930. DOI: 10.1158/1538-7445.Am2015-1930 |
0.289 |
|
2011 |
Carmack CL, Basen-Engquist K, Yuan Y, Greisinger A, Rodriguez-Bigas M, Wolff RA, Barker T, Baum G, Pennebaker JW. Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients: results of the Healthy Expressions study. Cancer. 117: 4993-5002. PMID 21480203 DOI: 10.1002/Cncr.26110 |
0.289 |
|
2013 |
Jin IH, Yuan Y, Liang F. Bayesian Analysis for Exponential Random Graph Models Using the Adaptive Exchange Sampler. Statistics and Its Interface. 6: 559-576. PMID 24653788 DOI: 10.4310/Sii.2013.V6.N4.A13 |
0.288 |
|
2019 |
Shin SJ, Yuan Y, Strong LC, Bojadzieva J, Wang W. Bayesian Semiparametric Estimation of Cancer-specific Age-at-onset Penetrance with Application to Li-Fraumeni Syndrome. Journal of the American Statistical Association. 114: 541-552. PMID 31485091 DOI: 10.1080/01621459.2018.1482749 |
0.287 |
|
2019 |
Zhu H, Chen K, Luo X, Yuan Y, Wang JL. FMEM: Functional Mixed Effects Models for Longitudinal Functional Responses. Statistica Sinica. 29: 2007-2033. PMID 31745381 DOI: 10.5705/Ss.202017.0505 |
0.286 |
|
2020 |
Yin J, Yuan Y. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials. Journal of Biopharmaceutical Statistics. 1-20. PMID 32966167 DOI: 10.1080/10543406.2020.1815033 |
0.286 |
|
2018 |
De Groot JF, Penas-Prado M, Mandel JJ, O'Brien BJ, Weathers SS, Zhou S, Hunter K, Alfaro-Munoz K, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, Ferguson SD, Yuan Y, et al. Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. Journal of Clinical Oncology. 36: 2008-2008. DOI: 10.1200/Jco.2018.36.15_Suppl.2008 |
0.284 |
|
2020 |
Zhang Q, Su X, Celestino J, Yuan Y, Mok SC, Lu KH, Yates MS. Abstract 4143: Identification of molecular targets for conservative management of early stage, low-grade endometrial cancer through compartment-specific transcriptome profiling Cancer Research. 80: 4143-4143. DOI: 10.1158/1538-7445.Am2020-4143 |
0.283 |
|
2021 |
Yuan Y, Wu J, Gilbert MR. BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials. Neuro-Oncology Practice. 8: 627-638. PMID 34777832 DOI: 10.1093/nop/npab035 |
0.281 |
|
2013 |
Schover LR, Yuan Y, Fellman BM, Odensky E, Lewis PE, Martinetti P. Efficacy trial of an Internet-based intervention for cancer-related female sexual dysfunction. Journal of the National Comprehensive Cancer Network. 11: 1389-1397. PMID 24225972 DOI: 10.6004/Jnccn.2013.0162 |
0.281 |
|
2011 |
Yin G, Ma Y, Liang F, Yuan Y. Stochastic Generalized Method of Moments. Journal of Computational and Graphical Statistics : a Joint Publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America. 20: 714-727. PMID 22375093 DOI: 10.1198/Jcgs.2011.09210 |
0.28 |
|
2020 |
Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, et al. Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer. American Journal of Obstetrics and Gynecology. PMID 32805208 DOI: 10.1016/J.Ajog.2020.08.032 |
0.279 |
|
2012 |
Yuan Y, Thall PF, Wolff JE. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. Journal of the Royal Statistical Society. Series C, Applied Statistics. 61: 135-149. PMID 22408277 DOI: 10.1111/J.1467-9876.2011.01002.X |
0.279 |
|
2019 |
de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology. PMID 31755915 DOI: 10.1093/Neuonc/Noz185 |
0.276 |
|
2019 |
Huang J, Yuan Y, Wetter D. Latent Class Dynamic Mediation Model with Application to Smoking Cessation Data. Psychometrika. PMID 30607659 DOI: 10.1007/S11336-018-09653-2 |
0.273 |
|
2016 |
Jin IH, Yuan Y, Bandyopadhyay D. A BAYESIAN HIERARCHICAL SPATIAL MODEL FOR DENTAL CARIES ASSESSMENT USING NON-GAUSSIAN MARKOV RANDOM FIELDS. The Annals of Applied Statistics. 10: 884-905. PMID 27807470 DOI: 10.1214/16-Aoas917 |
0.272 |
|
2014 |
Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells (Dayton, Ohio). 32: 301-12. PMID 24038660 DOI: 10.1002/Stem.1528 |
0.27 |
|
2016 |
Huang J, Yuan Y. Bayesian Dynamic Mediation Analysis. Psychological Methods. PMID 27123750 DOI: 10.1037/Met0000073 |
0.27 |
|
2022 |
Zhang W, Pan Z, Yuan Y. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data. Journal of Biopharmaceutical Statistics. 1-14. PMID 35679137 DOI: 10.1080/10543406.2022.2080700 |
0.27 |
|
2014 |
Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de-Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro-Oncology. 16: 409-13. PMID 24305706 DOI: 10.1200/Jco.2013.31.15_Suppl.2063 |
0.269 |
|
2015 |
Lilly MB, Ma C, Yuan Y, Chen W, Soloff AC, McLaren CE, Zi X. A phase I trial of docetaxel combined with synthetic lycopene in subjects with metastatic prostate cancer. Journal of Clinical Oncology. 33: e16109-e16109. DOI: 10.1200/Jco.2015.33.15_Suppl.E16109 |
0.269 |
|
2017 |
Armstrong TS, Gilbert MR, Bondy M, Sulman E, Yuan Y, Zhou R, Vera E, Wendland M, Pugh S, Scheurer M. OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825 Neuro-Oncology. 19: iii10-iii10. DOI: 10.1093/Neuonc/Nox036.033 |
0.269 |
|
2014 |
Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics. 70: 366-77. PMID 24575781 DOI: 10.1111/Biom.12146 |
0.268 |
|
2021 |
Schipper MJ, Yuan Y, Taylor JM, Ten Haken RK, Tsien C, Lawrence TS. A Bayesian dose-finding design for outcomes evaluated with uncertainty. Clinical Trials (London, England). 17407745211001521. PMID 33884907 DOI: 10.1177/17407745211001521 |
0.268 |
|
2012 |
Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. Plos One. 7: e45894. PMID 23029298 DOI: 10.1371/Journal.Pone.0045894 |
0.266 |
|
2018 |
Uc A, Perito ER, Pohl JF, Shah U, Abu-El-Haija M, Barth B, Bellin MD, Ellery KM, Fishman DS, Gariepy CE, Giefer MJ, Gonska T, Heyman MB, Himes RW, Husain SZ, ... ... Yuan Y, et al. INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPIRE 2 From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas. 47: 1222-1228. PMID 30325861 DOI: 10.1097/Mpa.0000000000001172 |
0.265 |
|
2020 |
Msaouel P, Thall PF, Yuan Y, Wang X, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam A, Ahrar K, Rao P, Sircar K, Der-Torossian H, Tannir NM. A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy. Journal of Clinical Oncology. 38: 612-612. DOI: 10.1200/Jco.2020.38.6_Suppl.612 |
0.264 |
|
2019 |
Yuan Y, Lee JJ, Hilsenbeck SG. Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. Jco Precision Oncology. 3. PMID 32923856 DOI: 10.1200/PO.19.00032 |
0.263 |
|
2019 |
Amaria RN, Bernatchez C, Forget M, Haymaker CL, Conley AP, Livingston JA, Varadhachary GR, Javle MM, Maitra A, Tzeng CD, Hinchcliff E, Bayer V, Gasior Y, Hilton T, Celestino J, ... ... Yuan Y, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps2650 |
0.263 |
|
2022 |
Zhao Y, Tang RS, Du Y, Yuan Y. A bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints. Biometrics. PMID 35546501 DOI: 10.1111/biom.13694 |
0.263 |
|
2012 |
Fingeret MC, Yuan Y, Urbauer D, Weston J, Nipomnick S, Weber RS. The nature and extent of body image concerns among surgically treated patients with head and neck cancer Psycho-Oncology. 21: 836-844. PMID 21706673 DOI: 10.1002/Pon.1990 |
0.262 |
|
2013 |
Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Research. 73: 3062-74. PMID 23492364 DOI: 10.1158/0008-5472.Can-12-2033 |
0.261 |
|
2012 |
Schover LR, Canada AL, Yuan Y, Sui D, Neese L, Jenkins R, Rhodes MM. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer. 118: 500-9. PMID 21953578 DOI: 10.1002/Cncr.26308 |
0.26 |
|
2021 |
Zhou X, Friedlander S, Kupperman E, Sedarati F, Kuroda S, Hua Z, Yuan Y, Yamamoto Y, Faller DV, Haikawa K, Nakai K, Bowen S, Dai Y, Venkatakrishnan K. Asia-Inclusive Global Development of Pevonedistat: Clinical Pharmacology and Translational Research Enabling a Phase III Multi-Regional Clinical Trial. Clinical and Translational Science. PMID 33503305 DOI: 10.1111/cts.12972 |
0.26 |
|
2021 |
Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials. Statistics in Biopharmaceutical Research. 13: 147-155. PMID 34249223 DOI: 10.1080/19466315.2020.1811147 |
0.26 |
|
2014 |
Castillo SJ, Castillo R, Balter P, Pan T, Ibbott G, Hobbs B, Yuan Y, Guerrero T. Assessment of a quantitative metric for 4D CT artifact evaluation by observer consensus. Journal of Applied Clinical Medical Physics / American College of Medical Physics. 15: 4718. PMID 24892346 DOI: 10.1120/Jacmp.V15I3.4718 |
0.259 |
|
2015 |
Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS. Venous thromboembolism (VTE) and glioblastoma. Journal of Neuro-Oncology. 124: 87-94. PMID 25985958 DOI: 10.1200/Jco.2014.32.15_Suppl.2033 |
0.259 |
|
2015 |
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology. 17: 440-7. PMID 25121770 DOI: 10.1093/Neuonc/Nou162 |
0.258 |
|
2021 |
Tidwell RSS, Thall PF, Yuan Y. Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. Jco Precision Oncology. 5. PMID 34805718 DOI: 10.1200/PO.21.00212 |
0.257 |
|
2013 |
Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim NK, Yerushalmi R, Penas-Prado M, Groves MD. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis Journal of Neuro-Oncology. 114: 229-235. PMID 23756727 DOI: 10.1007/S11060-013-1175-6 |
0.257 |
|
2011 |
Yuan Y, Yin G. On the usefulness of outcome-adaptive randomization. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e390-2; author reply. PMID 21422433 DOI: 10.1200/Jco.2010.34.5330 |
0.255 |
|
2012 |
Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 184-95. PMID 22065080 DOI: 10.1158/1078-0432.Ccr-11-1558 |
0.255 |
|
2020 |
Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks KJ, Yuan Y, Ali-Shaw T, Senese S, Westin J, Leonard JP. Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas. Journal of Clinical Oncology. 38: 8003-8003. DOI: 10.1200/Jco.2020.38.15_Suppl.8003 |
0.255 |
|
2017 |
Jiang H, Rivera-Molina Y, Clise-Dwyer K, Bover L, Vence L, Yuan Y, Lang FF, Toniatti C, Hossain MB, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Research. PMID 28566332 DOI: 10.1158/0008-5472.Can-17-0468 |
0.254 |
|
2015 |
Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. Journal of Neuro-Oncology. PMID 26566652 DOI: 10.1007/S11060-015-1992-X |
0.254 |
|
2018 |
Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen DR, Soletsky B, Milbourne A, Levy E, Fellman BM, Urbauer DL, Yuan Y, Broaddus RR, Basen-Engquist K, Lu K. Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese women at increased risk for endometrial cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 29716897 DOI: 10.1158/1940-6207.Capr-17-0398 |
0.251 |
|
2016 |
Katz LH, Advani S, Burton-Chase AM, Fellman B, Polivka KM, Yuan Y, Lynch PM, Peterson SK. Cancer screening behaviors and risk perceptions among family members of colorectal cancer patients with unexplained mismatch repair deficiency. Familial Cancer. PMID 27832499 DOI: 10.1007/S10689-016-9947-8 |
0.25 |
|
2021 |
Park Y, Liu S, Thall P, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics. PMID 33438761 DOI: 10.1111/biom.13421 |
0.248 |
|
2020 |
Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemporary Clinical Trials. 106216. PMID 33246098 DOI: 10.1016/j.cct.2020.106216 |
0.248 |
|
2017 |
Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm G, Yuan Y, Mok SC, Broaddus RJ, Lu K, Yates MS. Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28264871 DOI: 10.1158/1078-0432.Ccr-16-2655 |
0.246 |
|
2018 |
Kamiya-Matsuoka C, Metrus NR, Shaw KR, Penas-Prado M, Weathers SS, Loghin ME, Alfaro-Munoz K, Yuan Y, O'Brien BJ, Harrison RA, Yung WKA, Meric-Bernstam F, Groot JFD. The natural course of hypermutator gliomas. Journal of Clinical Oncology. 36: 2014-2014. DOI: 10.1200/Jco.2018.36.15_Suppl.2014 |
0.245 |
|
2021 |
Zhou Y, Lin R, Kuo YW, Lee JJ, Yuan Y. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. Jco Clinical Cancer Informatics. 5: 91-101. PMID 33439726 DOI: 10.1200/CCI.20.00122 |
0.245 |
|
2020 |
Westin SN, Lee S, Zhao L, Yuan Y, Wu J, Hajek R, Sharafi S, Meyer LA, Fleming ND, Jazaeri A, Coleman RL, Lu KH, Mills GB, Zhang J, Futreal A, et al. Abstract CT188: Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct188 |
0.245 |
|
2022 |
Qing Y, Thall PF, Yuan Y. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharmaceutical Statistics. PMID 35851545 DOI: 10.1002/pst.2256 |
0.244 |
|
2021 |
Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, ... ... Yuan Y, et al. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34237343 DOI: 10.1016/j.radonc.2021.06.037 |
0.243 |
|
2019 |
Uc A, Perito E, Pohl J, Shah U, Abu-El-Haija M, Appana S, Barth B, Bellin M, Ellery K, Fishman DS, Gariepy CE, Giefer MJ, Gonska T, Heyman M, Himes R, ... ... Yuan Y, et al. 651 – International Study Group of Pediatric Pancreatitis: in Search for a Cure(INSPPIRE 2) Cohort Study: Design and Rationale from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) Gastroenterology. 156: S-136. DOI: 10.1016/S0016-5085(19)37131-8 |
0.243 |
|
2019 |
Palermo TM, Murray C, Aalfs H, Abu-El-Haija M, Barth B, Bellin MD, Ellery K, Fishman DS, Gariepy CE, Giefer MJ, Goday P, Gonska T, Heyman MB, Husain SZ, Lin TK, ... ... Yuan Y, et al. Web-based cognitive-behavioral intervention for pain in pediatric acute recurrent and chronic pancreatitis: Protocol of a multicenter randomized controlled trial from the study of chronic pancreatitis, diabetes and pancreatic cancer (CPDPC). Contemporary Clinical Trials. 105898. PMID 31756383 DOI: 10.1016/J.Cct.2019.105898 |
0.243 |
|
2015 |
Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathologica. 129: 585-96. PMID 25701198 DOI: 10.1007/S00401-015-1398-Z |
0.243 |
|
2023 |
Hui C, Brown E, Wong S, Das M, Wakelee H, Neal J, Ramchandran K, Myall NJ, Pham D, Xing L, Yang Y, Kovalchuk N, Yuan Y, Lu Y, Xiang M, et al. Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. PMID 38040540 DOI: 10.1016/j.cllc.2023.11.004 |
0.242 |
|
2020 |
Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. Jco Precision Oncology. 4. PMID 33283133 DOI: 10.1200/PO.20.00257 |
0.241 |
|
2013 |
Zang Y, Yuan Y. A shrinkage method for testing the hardy-weinberg equilibrium in case-control studies Genetic Epidemiology. 37: 743-750. PMID 23934751 DOI: 10.1002/Gepi.21753 |
0.241 |
|
2020 |
Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. Journal of the American Statistical Association. 116: 322-334. PMID 35582047 DOI: 10.1080/01621459.2020.1837142 |
0.241 |
|
2019 |
Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31455679 DOI: 10.1158/1078-0432.Ccr-19-0405 |
0.237 |
|
2016 |
Zhang L, Yuan Y, Lu KH, Zhang L. Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer. Bmc Bioinformatics. 17: 222. PMID 27230211 DOI: 10.1186/S12859-016-1085-7 |
0.237 |
|
2020 |
Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma. Neuro-Oncology. PMID 33085768 DOI: 10.1093/neuonc/noaa240 |
0.235 |
|
2019 |
Shin SJ, Dodd E, Peng G, Bojadzieva J, Chen J, Ning J, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W. Abstract 2434: Characterizing age-of-onset of multiple primary cancers and specific cancer types in families with Li-Fraumeni syndrome Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2434 |
0.235 |
|
2015 |
Katz LH, Burton-Chase AM, Advani S, Fellman B, Polivka K, Yuan Y, Lynch PM, Peterson SK. Su1951 Screening Adherence and Cancer Risk Perceptions in Colorectal Cancer Survivors With Lynch-Like Syndrome Gastroenterology. 148. DOI: 10.1016/S0016-5085(15)31880-1 |
0.234 |
|
2022 |
van Dijk LV, Frank SJ, Yuan Y, Gunn B, Moreno AC, Mohamed ASR, Preston KE, Qing Y, Spiotto MT, Morrison WH, Lee A, Phan J, Garden AS, Rosenthal DI, Langendijk JA, et al. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clinical and Translational Radiation Oncology. 32: 35-40. PMID 34841093 DOI: 10.1016/j.ctro.2021.11.003 |
0.234 |
|
2011 |
Song PXK, Li M, Yuan Y. Rejoinder to “Joint Regression Analysis for Discrete Longitudinal Data” by Madsen and Fang Biometrics. 67: 1175-1176. DOI: 10.1111/J.1541-0420.2010.01495.X |
0.232 |
|
2013 |
Fingeret MC, Hutcheson KA, Jensen K, Yuan Y, Urbauer D, Lewin JS. Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer. Head & Neck. 35: 354-60. PMID 22431304 DOI: 10.1002/Hed.22980 |
0.23 |
|
2021 |
Park Y, Yuan Y, Ning J, Liu S, Feng Z. Hybrid design evaluating new biomarkers when there is an existing screening test. Statistics in Medicine. PMID 33540472 DOI: 10.1002/sim.8890 |
0.229 |
|
2016 |
Shen W, Ning J, Yuan Y. Rate-adaptive Bayesian independent component analysis Electronic Journal of Statistics. 10: 3247-3264. DOI: 10.1214/16-Ejs1183 |
0.228 |
|
2011 |
Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 117: 3900-7. PMID 21365619 DOI: 10.1002/Cncr.25971 |
0.228 |
|
2021 |
Kang D, S Coffey C, J Smith B, Yuan Y, Shi Q, Yin J. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Statistics in Medicine. PMID 33772843 DOI: 10.1002/sim.8946 |
0.228 |
|
2022 |
Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou X, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, et al. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. Journal of Hematology & Oncology. 15: 56. PMID 35545778 DOI: 10.1186/s13045-022-01264-w |
0.225 |
|
2021 |
Jiang L, Nie L, Yan F, Yuan Y. Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials. Contemporary Clinical Trials. 106460. PMID 34098036 DOI: 10.1016/j.cct.2021.106460 |
0.225 |
|
2023 |
Guo B, Yuan Y. DROID: Dose-ranging approach to optimizing dose in oncology drug development. Biometrics. PMID 36807110 DOI: 10.1111/biom.13840 |
0.224 |
|
2013 |
Shinn EH, Basen-Engquist K, Baum G, Steen S, Bauman RF, Morrison W, Garden AS, Sheil C, Kilgore K, Hutcheson KA, Barringer D, Yuan Y, Lewin JS. Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. Head & Neck. 35: 1707-12. PMID 24142523 DOI: 10.1002/Hed.23255 |
0.223 |
|
2023 |
Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials (London, England). 17407745231176445. PMID 37313712 DOI: 10.1177/17407745231176445 |
0.222 |
|
2021 |
Bahig H, Rosenthal DI, Nguyen-Tan FP, Fuller DC, Yuan Y, Hutcheson KA, Christopoulos A, Nichols AC, Fung K, Ballivy O, Filion E, Ng SP, Lambert L, Dorth J, Hu KS, et al. Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial. Bmc Cancer. 21: 446. PMID 33888069 DOI: 10.1186/s12885-021-08195-8 |
0.219 |
|
2015 |
Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, Lu KH, Su X. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. PMID 26431491 DOI: 10.18632/Oncotarget.5399 |
0.218 |
|
2021 |
Zhang W, Pan Z, Yuan Y. Elastic meta-analytic-predictive prior for dynamically borrowing information from historical data with application to biosimilar clinical trials. Contemporary Clinical Trials. 106559. PMID 34506959 DOI: 10.1016/j.cct.2021.106559 |
0.216 |
|
2009 |
Kiserud CE, Schover LR, Dahl AA, Fosså A, Bjøro T, Loge JH, Holte H, Yuan Y, Fosså SD. Do Male Lymphoma Survivors Have Impaired Sexual Function Journal of Clinical Oncology. 27: 6019-6026. PMID 19858388 DOI: 10.1200/Jco.2009.23.2280 |
0.214 |
|
2023 |
Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, ... ... Yuan Y, et al. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. Journal of Immunotherapy and Precision Oncology. 6: 10-18. PMID 36751659 DOI: 10.36401/JIPO-22-23 |
0.213 |
|
2020 |
Dottino JA, Zhang Q, Loose DS, Fellman B, Melendez BD, Waters MS, McKenzie LJ, Yuan Y, Yang RK, Broaddus RR, Lu KH, Soliman PT, Yates MS. Endometrial biomarkers in premenopausal obese women: an at-risk cohort. American Journal of Obstetrics and Gynecology. PMID 32835719 DOI: 10.1016/J.Ajog.2020.08.053 |
0.212 |
|
2015 |
Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Molecular Oncology. 9: 32-43. PMID 25126716 DOI: 10.1016/J.Molonc.2014.07.007 |
0.211 |
|
2023 |
He J, Liu Y, Liu C, Hu H, Sun L, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, ... ... Yuan Y, et al. A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technology in Cancer Research & Treatment. 22: 15330338231152350. PMID 36727222 DOI: 10.1177/15330338231152350 |
0.211 |
|
2018 |
Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. Jama. 319: 2486-2496. PMID 29946728 DOI: 10.1001/jama.2018.7855 |
0.211 |
|
2014 |
Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro-Oncology. 16: 1289-94. PMID 24615863 DOI: 10.1093/Neuonc/Nou019 |
0.211 |
|
2023 |
Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, ... ... Yuan Y, et al. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. The Lancet. Oncology. 24: 1387-1398. PMID 38039992 DOI: 10.1016/S1470-2045(23)00478-3 |
0.209 |
|
2020 |
Xu R, Qin S, Guo W, Bai Y, Deng Y, Yang L, Chen Z, Zhong H, Pan H, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, et al. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III tri1al. Future Oncology (London, England). PMID 33325251 DOI: 10.2217/fon-2020-0875 |
0.209 |
|
2023 |
Zhao Y, Li D, Liu R, Yuan Y. Bayesian optimal phase II designs with dual-criterion decision making. Pharmaceutical Statistics. PMID 36871961 DOI: 10.1002/pst.2296 |
0.208 |
|
2023 |
Jiang L, Yuan Y. Seamless Phase II/III Design: A Useful Strategy to Reduce the Sample Size for Dose Optimization. Journal of the National Cancer Institute. PMID 37243720 DOI: 10.1093/jnci/djad103 |
0.208 |
|
2022 |
Yuan Y, Zhao Y. Commentary on "Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies". Statistics in Medicine. 41: 5484-5490. PMID 36394102 DOI: 10.1002/sim.9496 |
0.206 |
|
2021 |
Park M, Liu S, Yap TA, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. Jama Network Open. 4: e2037563. PMID 33595664 DOI: 10.1001/jamanetworkopen.2020.37563 |
0.206 |
|
2014 |
Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H. Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells. Cancer Research. 74: 6731-2. PMID 25398854 DOI: 10.1158/0008-5472.Can-14-2966 |
0.205 |
|
2023 |
Yang P, Hubert SM, Futreal PA, Song X, Zhang J, Lee JJ, Wistuba I, Yuan Y, Zhang J, Li Z. A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing. Biorxiv : the Preprint Server For Biology. PMID 37961165 DOI: 10.1101/2023.10.24.563820 |
0.203 |
|
2016 |
Vera E, Scheurer M, Zhou R, Gilbert MR, Bondy M, Sulman E, Yuan Y, Liu Y, Wendland M, Brachman D, Bearden J, McGovern SL, Wilson S, Judy K, Robins HI, et al. ACTR-21. OCCURRENCE AND IMPLICATIONS OF MYELOSUPPRESSION DURING CONCURRENT THERAPY ON RTOG 0825 Neuro-Oncology. 18: vi6-vi6. DOI: 10.1093/Neuonc/Now212.020 |
0.203 |
|
2009 |
Kiserud CE, Schover LR, Fossaa A, Dahl AA, Loge JH, Bjoero T, Holte H, Yuan Y, Fossaa SD. Sexual function in male lymphoma survivors versus matched controls: Relationship to age, gonadal hormones, and quality of life. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9510. PMID 27964479 DOI: 10.1200/Jco.2009.27.15_Suppl.9510 |
0.203 |
|
2021 |
Jiang L, Nie L, Yuan Y. Elastic priors to dynamically borrow information from historical data in clinical trials. Biometrics. PMID 34437714 DOI: 10.1111/biom.13551 |
0.203 |
|
2022 |
How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers. 14. PMID 35954359 DOI: 10.3390/cancers14153695 |
0.2 |
|
2015 |
Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G, Huang S. FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Research. 75: 2337-48. PMID 25832656 DOI: 10.1158/0008-5472.Can-14-2800 |
0.199 |
|
2022 |
Wang F, He MM, Xiao J, Zhang YQ, Yuan XL, Fang WJ, Zhang Y, Wang W, Hu XH, Ma ZG, Yao YC, Zhuang ZX, Zhou FX, Ying JE, Yuan Y, et al. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35929990 DOI: 10.1158/1078-0432.CCR-22-0655 |
0.198 |
|
2007 |
Johnson V, Yuan Y. Comments on 'An exploratory test for an excess of significant findings' by JPA loannidis and TA Trikalinos. Clinical Trials (London, England). 4: 254-5; discussion 25. PMID 17715250 DOI: 10.1177/1740774507079437 |
0.198 |
|
2020 |
Uc A, Appana S, Cress G, Yuan Y, Lowe M. 1081 Sex Differences In Pediatric Acute Recurrent And Chronic Pancreatitis Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31210-5 |
0.197 |
|
2014 |
Harreld JH, Sabin ND, Rossi MG, Awwad R, Reddick WE, Yuan Y, Glass JO, Ji Q, Gajjar A, Patay Z. Elevated cerebral blood volume contributes to increased FLAIR signal in the cerebral sulci of propofol-sedated children. Ajnr. American Journal of Neuroradiology. 35: 1574-9. PMID 24699094 DOI: 10.3174/Ajnr.A3911 |
0.197 |
|
2020 |
Li J, Guo W, Bai Y, Deng Y, Yang L, Chen Z, Zhong H, Xu R, Pan H, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, et al. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. Advances in Therapy. PMID 32901330 DOI: 10.1007/s12325-020-01477-w |
0.197 |
|
2021 |
Ding Y, Weng S, Li X, Zhang D, Aisa A, Yuan Y. General treatment for metastatic colorectal cancer: From KEYNOTE 177 study. Translational Oncology. 14: 101122. PMID 34030111 DOI: 10.1016/j.tranon.2021.101122 |
0.197 |
|
2022 |
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, et al. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring Amplification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200830. PMID 36469840 DOI: 10.1200/JCO.22.00830 |
0.196 |
|
2012 |
Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 119: 4123-8. PMID 22371887 DOI: 10.1182/blood-2012-01-405456 |
0.195 |
|
2021 |
Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, Su YT, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, et al. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33785481 DOI: 10.1158/1078-0432.CCR-20-4730 |
0.195 |
|
2010 |
Yin G, Yuan Y. Authors’ response Journal of the Royal Statistical Society: Series C (Applied Statistics). 59: 544-546. DOI: 10.1111/J.1467-9876.2010.00710_2.X |
0.194 |
|
2021 |
Zhou X, Mould DR, Yuan Y, Fox E, Greengard E, Faller DV, Venkatakrishnan K. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. Journal of Clinical Pharmacology. PMID 34435684 DOI: 10.1002/jcph.1958 |
0.194 |
|
2023 |
Zhang Q, Zhang J, Zhong H, Yuan Y, Yang L, Zhang Q, Ji D, Gong J, Li J, Yao Z, Qi C, Wang J, Lu L, Shi M, Qian X, et al. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma. Cancer Immunology, Immunotherapy : Cii. PMID 37115210 DOI: 10.1007/s00262-023-03434-2 |
0.193 |
|
2022 |
Fu X, Ying J, Yang L, Fang W, Weidong H, Hu H, Zhang S, Yuan Y. Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: a phase 2 trial. Cancer Science. PMID 36382603 DOI: 10.1111/cas.15660 |
0.192 |
|
2020 |
Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, Deng YH, Xu JM, Bai YX, Wang Y, Liao WJ, Zhang HL, Bi F, Wang BM, Zhuang ZX, et al. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. American Journal of Cancer Research. 10: 3037-3046. PMID 33042632 |
0.19 |
|
2022 |
Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, et al. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine. 14: eabm6420. PMID 35442707 DOI: 10.1126/scitranslmed.abm6420 |
0.189 |
|
2021 |
Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, et al. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34518313 DOI: 10.1158/1078-0432.CCR-21-1656 |
0.189 |
|
2020 |
Tham SW, Cress G, Yuan Y, Appana S, Lowe M, Uc A, Gariepy CE, Palermo TM. Su1505 HEALTH-RELATED QUALITY OF LIFE, EMOTIONAL, AND BEHAVIORAL FUNCTIONING IN CHILDREN WITH ACUTE RECURRENT OR CHRONIC PANCREATITIS Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)32219-8 |
0.188 |
|
2019 |
Tan Y, Fu D, Li D, Kong X, Jiang K, Chen L, Yuan Y, Ding K. Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis. Frontiers in Oncology. 9: 497. PMID 31263674 DOI: 10.3389/fonc.2019.00497 |
0.187 |
|
2015 |
Zhang S, Gong A, Wei P, Zhou A, Yao J, Yuan Y, Lang F, Rao G, Huang S. Abstract 2099: FoxM1 drives a feed-forward STAT3-activation signaling loop to promote the self-renewal and tumorigenicity of glioblastoma stem cells Cancer Research. 75: 2099-2099. DOI: 10.1158/1538-7445.Am2015-2099 |
0.187 |
|
2022 |
Li J, Cheng Y, Bai C, Xu J, Shen L, Li J, Zhou Z, Li Z, Chi Y, Yu X, Li E, Xu N, Liu T, Lou W, Bai Y, ... ... Yuan Y, et al. Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9]. European Journal of Cancer (Oxford, England : 1990). PMID 36402625 DOI: 10.1016/j.ejca.2022.10.001 |
0.187 |
|
2023 |
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, Xu J, Zhang H, Chen J, Yuan Y, Liu T, Yang L, Zhong H, Chen D, Shen L, et al. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202630. PMID 37647576 DOI: 10.1200/JCO.22.02630 |
0.186 |
|
2013 |
Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, Groot Jd, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, ... ... Yuan Y, et al. Neuro/Medical Oncology Neuro-Oncology. 15: 120-120. DOI: 10.1093/Neuonc/Not182 |
0.184 |
|
2021 |
Zhou Y, Lee JJ, Wang S, Bailey S, Yuan Y. Incorporating historical information to improve phase I clinical trials. Pharmaceutical Statistics. PMID 33793044 DOI: 10.1002/pst.2121 |
0.184 |
|
2020 |
Yang M, Zhong X, Yuan Y. Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review. Integrative Cancer Therapies. 19: 1534735420922579. PMID 32448009 DOI: 10.1177/1534735420922579 |
0.181 |
|
2023 |
Yang P, Zhao Y, Nie L, Vallejo J, Yuan Y. SAM: Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Biometrics. PMID 37721513 DOI: 10.1111/biom.13927 |
0.179 |
|
2022 |
Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Frontiers in Immunology. 13: 1027235. PMID 36439116 DOI: 10.3389/fimmu.2022.1027235 |
0.178 |
|
2019 |
Li D, Zhong C, Cheng Y, Zhu N, Tan Y, Zhu L, Xu D, Yuan Y. A Competing Nomogram to Predict Survival Outcomes in Invasive Micropapillary Breast Cancer. Journal of Cancer. 10: 6801-6812. PMID 31839814 DOI: 10.7150/jca.27955 |
0.174 |
|
2022 |
Aisa A, Weng S, Li X, Zhang D, Yuan Y. Immune Checkpoint Inhibitors combined with HER-2 targeted therapy in HER-2 positive Gastroesophageal cancer. Critical Reviews in Oncology/Hematology. 103864. PMID 36332788 DOI: 10.1016/j.critrevonc.2022.103864 |
0.173 |
|
2017 |
Li X, Ma T, Zhang Q, Chen YG, Guo CX, Shen YN, Sun PW, Li GG, Gao SL, Que RS, Lou JY, Yu RS, Yuan Y, Wei QC, Wei SM, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population. Cancer Letters. PMID 28729048 DOI: 10.1016/j.canlet.2017.07.012 |
0.173 |
|
2014 |
Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. Plos One. 9: e108405. PMID 25247558 DOI: 10.1371/journal.pone.0108405 |
0.173 |
|
2021 |
Melendez B, Shah S, Jiang Y, Dottino J, Watson E, Pearce H, Borthwick M, Schmandt RE, Zhang Q, Cumpian K, Celestino J, Fellman B, Yuan Y, Lu KH, Mikos AG, et al. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 34648891 DOI: 10.1016/j.jconrel.2021.10.008 |
0.172 |
|
2018 |
Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, Hu H, Weng S, Ding K, Yuan Y. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biology & Therapy. 1-6. PMID 30307354 DOI: 10.1080/15384047.2018.1529120 |
0.171 |
|
2023 |
Li J, Qin S, Wen L, Wang J, Deng W, Guo W, Jia T, Jiang D, Zhang G, He Y, Ba Y, Zhong H, Wang L, Lin X, Yang J, ... ... Yuan Y, et al. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study. Bmc Medicine. 21: 173. PMID 37147645 DOI: 10.1186/s12916-023-02841-7 |
0.167 |
|
2021 |
Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, et al. Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. Oncotargets and Therapy. 14: 4439-4450. PMID 34408440 DOI: 10.2147/OTT.S307273 |
0.167 |
|
2021 |
Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, et al. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neuro-Oncology Advances. 3: vdab079. PMID 34377987 DOI: 10.1093/noajnl/vdab079 |
0.165 |
|
2019 |
Li J, Kong XX, Zhou JJ, Song YM, Huang XF, Li GH, Ying XJ, Dai XY, Lu M, Jiang K, Fu DL, Li XL, He JJ, Wang JW, Sun LF, ... ... Yuan Y, et al. Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study. Bmc Cancer. 19: 988. PMID 31647032 DOI: 10.1186/S12885-019-6188-X |
0.165 |
|
2023 |
Li Y, Cheng X, Zhong C, Yuan Y. Primary Tumor Resection Plus Chemotherapy versus Chemotherapy Alone for Colorectal Cancer Patients with Synchronous Bone Metastasis. Medicina (Kaunas, Lithuania). 59. PMID 37629673 DOI: 10.3390/medicina59081384 |
0.165 |
|
2020 |
Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology. PMID 32966811 DOI: 10.1016/S1470-2045(20)30496-4 |
0.162 |
|
2023 |
Cao H, Yao C, Yuan Y. Bayesian approach for design and analysis of medical device trials in the era of modern clinical studies. Medical Review (2021). 3: 408-424. PMID 38283256 DOI: 10.1515/mr-2023-0026 |
0.159 |
|
2021 |
How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers. 13. PMID 33668244 DOI: 10.3390/cancers13050946 |
0.158 |
|
2016 |
Zhu L, Dong C, Cao Y, Fang X, Zhong C, Li D, Yuan Y. Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials. Plos One. 11: e0154795. PMID 27138801 DOI: 10.1371/journal.pone.0154795 |
0.157 |
|
2022 |
Yuan Y, Li D, Hu X, Li Y, Yi W, Li P, Zhao Y, Li Z, Yu A, Jian C, Yu A. Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model. Medical Oncology (Northwood, London, England). 39: 87. PMID 35478053 DOI: 10.1007/s12032-022-01684-1 |
0.156 |
|
2020 |
Lu W, Fu D, Kong X, Huang Z, Hwang M, Zhu Y, Chen L, Jiang K, Li X, Wu Y, Li J, Yuan Y, Ding K. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms. Cancer Medicine. PMID 31893575 DOI: 10.1002/cam4.2786 |
0.156 |
|
2022 |
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, ... ... Yuan Y, et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Communications (London, England). PMID 36336841 DOI: 10.1002/cac2.12385 |
0.156 |
|
2018 |
Yao D, Shen H, Huang J, Yuan Y, Dai H. Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: A retrospective observational study. Medicine. 97: e11822. PMID 30095656 DOI: 10.1097/MD.0000000000011822 |
0.155 |
|
2018 |
Cai W, Yuan Y, Ge W, Fan Y, Liu X, Wu D, Hu H. EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs. Journal of Cancer. 9: 1476-1485. PMID 29721058 DOI: 10.7150/jca.23290 |
0.154 |
|
2022 |
Liu Y, Xiao Q, He J, Hu H, Du J, Zhu Y, Chen J, Liu Z, Wang J, Sun L, Xu D, Li J, Liao X, Wang J, Cai Y, ... ... Yuan Y, et al. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. Bmc Medicine. 20: 155. PMID 35513832 DOI: 10.1186/s12916-022-02357-6 |
0.153 |
|
2021 |
Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. The Lancet. Haematology. PMID 34634256 DOI: 10.1016/S2352-3026(21)00273-8 |
0.152 |
|
2022 |
Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, Santini V, Fram RJ, ... Yuan Y, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast percentage AML. Blood Advances. PMID 35728048 DOI: 10.1182/bloodadvances.2022007334 |
0.151 |
|
2019 |
Cheng Y, Weng S, Yu L, Zhu N, Yang M, Yuan Y. The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors. Integrative Cancer Therapies. 18: 1534735419876345. PMID 31522574 DOI: 10.1177/1534735419876345 |
0.151 |
|
2021 |
Yuan Y, Zhou Q, Fang F, Li W, You Y. Efficacy of the acupressure wrist-ankle strap in mild insomnia patients with anxiety disorders: study protocol for a randomized controlled trial. Trials. 22: 770. PMID 34736490 DOI: 10.1186/s13063-021-05725-4 |
0.151 |
|
2011 |
Yuan Y, Shen H, Hu XY, Gu FY, Li MD, Zhong X. Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Medical Oncology (Northwood, London, England). 29: 957-61. PMID 21387165 DOI: 10.1007/s12032-011-9892-1 |
0.151 |
|
2015 |
Li XF, Tan YN, Cao Y, Xu JH, Zheng S, Yuan Y. A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer. Medicine. 94: e1661. PMID 26426663 DOI: 10.1097/MD.0000000000001661 |
0.15 |
|
2022 |
Li J, Cheng Y, Bai C, Xu J, Shen L, Li J, Zhou Z, Li Z, Chi Y, Yu X, Li E, Xu N, Liu T, Lou W, Bai Y, ... ... Yuan Y, et al. Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). European Journal of Cancer (Oxford, England : 1990). 169: 1-9. PMID 35489301 DOI: 10.1016/j.ejca.2022.03.027 |
0.149 |
|
2022 |
Chaftari AM, Hachem R, Malek AE, Mulanovich VE, Szvalb AD, Jiang Y, Yuan Y, Ali S, Deeba R, Chaftari P, Raad I. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infectious Diseases. 9: ofac079. PMID 35663286 DOI: 10.1093/ofid/ofac079 |
0.147 |
|
2018 |
Peng J, Dong C, Wang C, Li W, Yu H, Zhang M, Zhao Q, Zhu B, Zhang J, Li W, Wang F, Wu Q, Zhou W, Yuan Y, Qiu M, et al. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer Communications (London, England). 38: 22. PMID 29764506 DOI: 10.1186/s40880-018-0292-1 |
0.147 |
|
2023 |
Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, et al. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. PMID 38009662 DOI: 10.1002/cncr.35126 |
0.147 |
|
2022 |
Yuan Y, Wang X, Shi M, Wang P. Performance comparison of RGB and multispectral vegetation indices based on machine learning for estimating SPAD values under different shade conditions. Frontiers in Plant Science. 13: 928953. PMID 35937316 DOI: 10.3389/fpls.2022.928953 |
0.145 |
|
2024 |
Li J, Hu YT, Liu CC, Wang LH, Ju HX, Huang XF, Chi P, Du JL, Wang JP, Xiao Y, Lin GL, Zhang W, Zhao H, Liu M, Song YM, ... ... Yuan Y, et al. Primary surgery followed by selective chemoradiotherapy versus preoperative chemoradiotherapy followed by surgery for locally advanced rectal cancer: A Randomized Clinical Trial. International Journal of Radiation Oncology, Biology, Physics. PMID 38185388 DOI: 10.1016/j.ijrobp.2023.12.027 |
0.144 |
|
2020 |
Zhang H, Fang X, Li D, Yang M, Yu L, Ding Y, Shen H, Yuan Y. Hyperprogressive disease in patients receiving immune checkpoint inhibitors. Current Problems in Cancer. 100688. PMID 33334611 DOI: 10.1016/j.currproblcancer.2020.100688 |
0.144 |
|
2022 |
Ye C, Lu Y, Yuan Z, Mi M, Qi L, Yuan Y, Weng S. Ferroptosis regulator FANCD2 is associated with immune infiltration and predicts worse prognosis in lung adenocarcinoma. Frontiers in Genetics. 13: 922914. PMID 36267413 DOI: 10.3389/fgene.2022.922914 |
0.143 |
|
2012 |
Yuan Y, Tan CW, Shen H, Yu JK, Fang XF, Jiang WZ, Zheng S. Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks. Hepato-Gastroenterology. 59: 2461-5. PMID 22497949 DOI: 10.5754/hge12127 |
0.142 |
|
2021 |
Yi X, Cao Z, Yuan Y, Li W, Cui X, Chen Z, Hu X, Yu A. Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a PIM1 kinase inhibitor. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 33662457 DOI: 10.1016/j.jconrel.2021.02.028 |
0.142 |
|
2021 |
Iwasa S, Muro K, Morita S, Park YS, Nakamura M, Kotaka M, Nishina T, Matsuoka H, Ahn JB, Lee KW, Hong YS, Han SW, Cho SH, Zhang DS, Fang WJ, ... ... Yuan Y, et al. Impact of UGT1A1 Genotype on the Efficacy and Safety of Irinotecan-based Chemotherapy in Metastatic Colorectal Cancer. Cancer Science. PMID 34327766 DOI: 10.1111/cas.15092 |
0.142 |
|
2022 |
Ng SP, Cardenas CE, Bahig H, Elgohari B, Wang J, Johnson JM, Moreno AC, Shah SJ, Garden AS, Phan J, Gunn GB, Frank SJ, Ding Y, Na L, Yuan Y, et al. Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. Current Oncology (Toronto, Ont.). 29: 6303-6313. PMID 36135064 DOI: 10.3390/curroncol29090495 |
0.142 |
|
2018 |
Li D, Zhong C, Tang X, Yu L, Ding K, Yuan Y. Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology. PMID 29460089 DOI: 10.1007/s00432-018-2611-y |
0.142 |
|
2022 |
Lu M, Liu S, Yuan Y. Why there are so many contradicted or exaggerated findings in highly-cited clinical research? Contemporary Clinical Trials. 118: 106782. PMID 35525531 DOI: 10.1016/j.cct.2022.106782 |
0.141 |
|
2022 |
Ge X, Li D, Ye X, Ma R, Yuan Y. A clinical prediction model for the presence of brain metastases from colorectal cancer. International Journal of Colorectal Disease. 37: 2469-2480. PMID 36459181 DOI: 10.1007/s00384-022-04289-2 |
0.141 |
|
2012 |
Hu H, Zhang H, Ge W, Liu X, Loera S, Chu P, Chen H, Peng J, Zhou L, Yu S, Yuan Y, Zhang S, Lai L, Yen Y, Zheng S. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5438-48. PMID 22891198 DOI: 10.1158/1078-0432.CCR-12-0124 |
0.141 |
|
2023 |
Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau FI, Radford J, de Oteyza JP, Zinzani PL, Iyer SP, ... ... Yuan Y, et al. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 14: 57-70. PMID 36702329 DOI: 10.18632/oncotarget.28352 |
0.14 |
|
2016 |
Yuan X, Wu X, Tian H, Yuan Y, Adnan RM. Parameter Identification of Nonlinear Muskingum Model with Backtracking Search Algorithm Water Resources Management. 1-17. DOI: 10.1007/s11269-016-1321-y |
0.14 |
|
2021 |
Xu J, Dai S, Jiang K, Xiao Q, Yuan Y, Ding K. Combining single-cell sequencing to identify key immune genes and construct the prognostic evaluation model for colon cancer patients. Clinical and Translational Medicine. 11: e465. PMID 34323426 DOI: 10.1002/ctm2.465 |
0.139 |
|
2020 |
Weng S, Zhu N, Li D, Chen Y, Tan Y, Chen J, Yuan Y. Clinical Characteristics, Treatment, and Prognostic Factors of Patients With Primary Extramammary Paget's Disease (EMPD): A Retrospective Analysis of 44 Patients From a Single Center and an Analysis of Data From the Surveillance, Epidemiology, and End Results (SEER) Database. Frontiers in Oncology. 10: 1114. PMID 32983958 DOI: 10.3389/fonc.2020.01114 |
0.139 |
|
2023 |
Ye X, Tan Y, Ma R, Lou P, Yuan Y. Radiation Therapy Changed the Second Malignancy Pattern in Rectal Cancer Survivors. Medicina (Kaunas, Lithuania). 59. PMID 37629753 DOI: 10.3390/medicina59081463 |
0.138 |
|
2022 |
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, et al. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 28: 1735. PMID 35419587 DOI: 10.1158/1078-0432.CCR-22-0468 |
0.138 |
|
2021 |
Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park YL, Koo DH, Lu J, Xu J, Chon HJ, Bai LY, Zeng S, Yuan Y, Chen YY, et al. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer. PMID 34878659 DOI: 10.1002/cncr.34019 |
0.138 |
|
2023 |
Yuan Y, Liu Q, Yang S, He W. Four-Dimensional Superimposition Techniques to Compose Dental Dynamic Virtual Patients: A Systematic Review. Journal of Functional Biomaterials. 14. PMID 36662080 DOI: 10.3390/jfb14010033 |
0.138 |
|
2021 |
Bai R, Tan Y, Li D, Yang M, Yu L, Yuan Y, Fang X. Development and validation of a novel prognostic nomogram including tumor deposits could better predict survival for colorectal cancer: a population-based study. Annals of Translational Medicine. 9: 620. PMID 33987318 DOI: 10.21037/atm-20-4728 |
0.137 |
|
2020 |
Zhou Y, Cheng X, Zhang F, Chen Q, Chen X, Shen Y, Lai C, Kota VG, Sun W, Huang Q, Yuan Y, Wang J, Lai M, Zhang D. Integrated Multi-omics Data Analyses for Exploring the Co-occurring and Mutually Exclusive Gene Alteration Events in Colorectal Cancer. Human Mutation. PMID 32485022 DOI: 10.1002/humu.24059 |
0.137 |
|
2020 |
Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, ... ... Yuan Y, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology. PMID 32966810 DOI: 10.1016/S1470-2045(20)30493-9 |
0.137 |
|
2023 |
Yao D, He W, Hu Y, Yuan Y, Xu H, Wang J, Dai H. Prevalence and influencing factors of probiotic usage among colorectal cancer patients in China: A national database study. Plos One. 18: e0291864. PMID 37733795 DOI: 10.1371/journal.pone.0291864 |
0.136 |
|
2018 |
Li X, Guo C, Li Q, Wei S, Zhang Q, Chen Y, Shen Y, Ma T, Li G, Gao S, Que R, Lou J, Yu R, Yuan Y, Wei Q, et al. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. The Oncologist. PMID 30459238 DOI: 10.1634/theoncologist.2018-0696 |
0.136 |
|
2016 |
Xu RH, Shen L, Li J, Xu JM, Bi F, Ba Y, Bai L, Shu YQ, Liu TS, Li YH, Bai CM, Yuan XL, Zhang J, Chen G, Zhou AP, ... Yuan Y, et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chinese Journal of Cancer. 35: 13. PMID 26769299 DOI: 10.1186/s40880-015-0067-x |
0.136 |
|
2023 |
Fang X, Zhong C, Weng S, Hu H, Wang J, Xiao Q, Wang J, Sun L, Xu D, Liao X, Dong C, Zhang S, Li J, Ding K, Yuan Y. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. Bmc Cancer. 23: 676. PMID 37464378 DOI: 10.1186/s12885-023-11139-z |
0.135 |
|
2023 |
Han MJ, Pan M, Xiao G, Yuan Y, Chen S, Zou Z. Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents. Molecules (Basel, Switzerland). 28. PMID 37375183 DOI: 10.3390/molecules28124628 |
0.135 |
|
2021 |
Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro-Oncology. PMID 34059921 DOI: 10.1093/neuonc/noab128 |
0.135 |
|
2017 |
Jiang M, Tan Y, Li X, Fu J, Hu H, Ye X, Cao Y, Xu J, Yuan Y. Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms. Gastroenterology Research and Practice. 2017: 4206172. PMID 28194176 DOI: 10.1155/2017/4206172 |
0.134 |
|
2020 |
Ding Y, Wang J, Zhu N, Xu D, Ding K, Yuan Y. Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review. Cancer Biology & Therapy. 1-4. PMID 33151122 DOI: 10.1080/15384047.2020.1836549 |
0.134 |
|
2011 |
Chow SM, Tang N, Yuan Y, Song X, Zhu H. Bayesian estimation of semiparametric nonlinear dynamic factor analysis models using the Dirichlet process prior. The British Journal of Mathematical and Statistical Psychology. 64: 69-106. PMID 21506946 DOI: 10.1348/000711010X497262 |
0.131 |
|
2022 |
Zhu N, Zhao Y, Mi M, Lu Y, Tan Y, Fang X, Weng S, Yuan Y. REV1: A novel biomarker and potential therapeutic target for various cancers. Frontiers in Genetics. 13: 997970. PMID 36246647 DOI: 10.3389/fgene.2022.997970 |
0.131 |
|
2019 |
Zhu N, Weng S, Wang J, Chen J, Yu L, Fang X, Yuan Y. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. Journal of Cancer Research and Clinical Oncology. PMID 31617075 DOI: 10.1007/s00432-019-03044-5 |
0.131 |
|
2007 |
Tang B, Zhang S, Zhou X, Wang D, Yuan Y. Regression Analysis for Complex Doping of X8R Ceramics Based on Uniform Design Journal of Electronic Materials. 36: 1383-1388. DOI: 10.1007/s11664-007-0271-9 |
0.13 |
|
2021 |
Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, et al. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology. PMID 33551196 DOI: 10.1016/j.ygyno.2021.01.022 |
0.13 |
|
2022 |
Sun CY, Yuan Y, Yan SY. [Clinical effect and safety of filiform-fire needle in treatment of peripheral facial paralysis: a Meta-analysis]. Zhen Ci Yan Jiu = Acupuncture Research. 47: 274-81. PMID 35319847 DOI: 10.10372/j.1000-0607.20210559 |
0.129 |
|
2021 |
Xiao J, Liu Q, Wu W, Yuan Y, Zhou J, Shi J, Zhou S. Elevated Ras related GTP binding B (RRAGB) expression predicts poor overall survival and constructs a prognostic nomogram for colon adenocarcinoma. Bioengineered. 12: 4620-4632. PMID 34320917 DOI: 10.1080/21655979.2021.1956402 |
0.129 |
|
2016 |
Bai XL, Su RG, Ma T, Shen SC, Li GG, Lou JY, Gao SL, Que RS, Yuan Y, Yu RS, Wei QC, Liang TB. [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]. 54: 270-5. PMID 27029201 DOI: 10.3760/cma.j.issn.0529-5815.2016.04.006 |
0.129 |
|
2023 |
Hui X, Wang Y, Li W, Yuan Y, Tao X, Lv R. Nd-Mn Molecular Cluster with Searched Targets for Oral Cancer Imaging. Molecular Imaging and Biology. PMID 37256508 DOI: 10.1007/s11307-023-01828-3 |
0.129 |
|
2022 |
Luo L, Lin J, Deng Y, Li Z, Yuan Y, Zhang W. Treatment of progressive ischemic stroke with low‑dose eptifibatide: A retrospective case‑control study. Experimental and Therapeutic Medicine. 25: 22. PMID 36561618 DOI: 10.3892/etm.2022.11721 |
0.129 |
|
2019 |
Cai W, Ge W, Yuan Y, Ding K, Tan Y, Wu D, Hu H. A 10-year Population-based Study of the Differences between NECs and Carcinomas of the Esophagus in Terms of Clinicopathology and Survival. Journal of Cancer. 10: 1520-1527. PMID 31031862 DOI: 10.7150/jca.29483 |
0.128 |
|
2021 |
Zhu N, Fang X, Li D, Yang M, Zhu L, Zhong L, Weng S, Wang J, Yuan Y. Identification and prognostic analysis of the cetuximab resistance-related gene in wild-type metastatic colorectal cancer. American Journal of Cancer Research. 11: 2769-2781. PMID 34249427 |
0.127 |
|
2014 |
Yuan Y, Li MD, Hu HG, Dong CX, Chen JQ, Li XF, Li JJ, Shen H. Prognostic and survival analysis of 837 Chinese colorectal cancer patients. World Journal of Gastroenterology. 19: 2650-9. PMID 23674872 DOI: 10.3748/wjg.v19.i17.2650 |
0.127 |
|
2021 |
Yuan Y, Zhu C, Liu M, Zhou Y, Yang X, Zheng B, Li Z, Mao X, Ke B. Efficacy of combined orthokeratology and 0.01% atropine for myopia control: the study protocol for a randomized, controlled, double-blind, and multicenter trial. Trials. 22: 863. PMID 34852833 DOI: 10.1186/s13063-021-05825-1 |
0.127 |
|
2022 |
Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Youssef EF, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, et al. Germline polymorphisms in associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-Oncology Advances. 4: vdac152. PMID 36299794 DOI: 10.1093/noajnl/vdac152 |
0.126 |
|
2014 |
Yuan Y, Gilmore JH, Geng X, Martin S, Chen K, Wang JL, Zhu H. FMEM: functional mixed effects modeling for the analysis of longitudinal white matter Tract data. Neuroimage. 84: 753-64. PMID 24076225 DOI: 10.1016/J.Neuroimage.2013.09.020 |
0.125 |
|
2019 |
Li D, Weng S, Zhong C, Tang X, Zhu N, Cheng Y, Xu D, Yuan Y. Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer. Frontiers in Oncology. 9: 1426. PMID 31998630 DOI: 10.3389/fonc.2019.01426 |
0.125 |
|
2018 |
Zhao J, Xiao Z, Li T, Chen H, Yuan Y, Wang AY, Hsiao CH, Chow DS, Overwijk WW, Li C. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. Acs Nano. PMID 30231203 DOI: 10.1021/Acsnano.8B02481 |
0.125 |
|
2023 |
Fang X, Zhu N, Zhong C, Wang L, Li J, Weng S, Hu H, Dong C, Li D, Song Y, Xu D, Wang J, Sun L, Wang J, Wang Z, ... ... Yuan Y, et al. Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial. Eclinicalmedicine. 62: 102123. PMID 37554125 DOI: 10.1016/j.eclinm.2023.102123 |
0.125 |
|
2020 |
Ren J, Qi M, Yuan Y, Duan S, Tao X. Machine Learning-Based MRI Texture Analysis to Predict the Histologic Grade of Oral Squamous Cell Carcinoma. Ajr. American Journal of Roentgenology. 1-7. PMID 32930606 DOI: 10.2214/AJR.19.22593 |
0.125 |
|
2015 |
Shen H, Fang XF, Yuan Y, Yang J, Zheng S. Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma. World Journal of Oncology. 6: 292-296. PMID 29147418 DOI: 10.14740/wjon901w |
0.124 |
|
2022 |
Li H, Xiang X, Ding H, Yu J, Xu J, Yuan Y, Wu Y. Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA. British Journal of Haematology. PMID 36169236 DOI: 10.1111/bjh.18476 |
0.124 |
|
2022 |
Cai L, Wang Z, Lin B, Liu K, Wang Y, Yuan Y, Tao X, Lv R. Rare earth nanoparticles for sprayed and intravenous NIR II imaging and photodynamic therapy of tongue cancer. Nanoscale Advances. 4: 2224-2232. PMID 36133451 DOI: 10.1039/d2na00197g |
0.124 |
|
2020 |
Xu J, Dai S, Yuan Y, Xiao Q, Ding K. A Prognostic Model for Colon Cancer Patients Based on Eight Signature Autophagy Genes. Frontiers in Cell and Developmental Biology. 8: 602174. PMID 33324651 DOI: 10.3389/fcell.2020.602174 |
0.124 |
|
2016 |
Shen H, Cao Y, Li X, Tan Y, Chen J, Yang Z, Kong Y, Yuan Y. Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients. Medicine. 95: e3800. PMID 27227958 DOI: 10.1097/MD.0000000000003800 |
0.124 |
|
2015 |
Ye J, Li XF, Wang YD, Yuan Y. Long-term survival of a patient with scalp angiosarcoma and multiple metastases treated using combination therapy: A case report. Oncology Letters. 9: 1725-1728. PMID 25789030 DOI: 10.3892/ol.2015.2919 |
0.123 |
|
2022 |
Mei WJ, Mi M, Qian J, Xiao N, Yuan Y, Ding PR. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review. Frontiers in Immunology. 13: 1019582. PMID 36618386 DOI: 10.3389/fimmu.2022.1019582 |
0.123 |
|
2017 |
Hu Y, Xiao Q, Chen H, He J, Tan Y, Liu Y, Wang Z, Yang Q, Shen X, Huang Y, Yuan Y, Ding K. BEX2 promotes tumor proliferation in colorectal cancer. International Journal of Biological Sciences. 13: 286-294. PMID 28367093 DOI: 10.7150/ijbs.15171 |
0.122 |
|
2019 |
Chen L, Jiang K, Chen H, Tang Y, Zhou X, Tan Y, Yuan Y, Xiao Q, Ding K. Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway. Cancer Management and Research. 11: 95-105. PMID 30588113 DOI: 10.2147/CMAR.S169476 |
0.122 |
|
2022 |
Cai L, Wang Y, Peng X, Li W, Yuan Y, Tao X, Yao X, Lv R. Gold Nanostars Combined with the Searched Antibody for Targeted Oral Squamous Cell Carcinoma Therapy. Acs Biomaterials Science & Engineering. PMID 35603744 DOI: 10.1021/acsbiomaterials.2c00276 |
0.121 |
|
2013 |
Zheng S, Shen Y, Song Y, Yuan Y. How to detour Treg cells in T cell-based antitumor immune therapy. Oncotargets and Therapy. 6: 1243-7. PMID 24043948 DOI: 10.2147/OTT.S48872 |
0.121 |
|
2016 |
Yuan Y, Wang W, Chu X, Xi MJ. [Selection of Characteristic Wavelengths Using SPA and Qualitative Discrimination of Mildew Degree of Corn Kernels Based on SVM]. Guang Pu Xue Yu Guang Pu Fen Xi = Guang Pu. 36: 226-30. PMID 27228772 |
0.121 |
|
2016 |
Yuan Y, Wang J, Wu Y, Li G, Tao X. Can preoperative computed tomography predict tissue origin of primary maxillary cancer? Medicine. 95: e4831. PMID 27749536 DOI: 10.1097/MD.0000000000004831 |
0.12 |
|
2022 |
Wang H, Li X, Yuan Y, Tong Y, Zhu S, Huang R, Shen K, Guo Y, Wang Y, Chen X. Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer. American Journal of Cancer Research. 12: 152-164. PMID 35141010 |
0.12 |
|
2024 |
Lai K, Wang J, Lin S, Chen Z, Lin G, Ye K, Yuan Y, Lin Y, Zhong CQ, Wu J, Ma H, Xu Y. Sensing of mitochondrial DNA by ZBP1 promotes RIPK3-mediated necroptosis and ferroptosis in response to diquat poisoning. Cell Death and Differentiation. PMID 38493248 DOI: 10.1038/s41418-024-01279-5 |
0.12 |
|
2024 |
Fan L, Liu J, Hu W, Chen Z, Lan J, Zhang T, Zhang Y, Wu X, Zhong Z, Zhang D, Zhang J, Qin R, Chen H, Zong Y, Zhang J, ... ... Yuan Y, et al. Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans. Cell Research. PMID 38491170 DOI: 10.1038/s41422-024-00945-0 |
0.12 |
|
2024 |
Xu J, Hu Y, Zhao J, Kong X, Xia S, Dai S, Ding L, Bu T, Cao Y, Liu M, Yan L, Xiao Q, Guo H, Yuan Y, Xu D, et al. Single-cell sequencing reveals alterations in the peripheral blood mononuclear cell landscape and monocyte status during colorectal adenocarcinoma formation. Clinical and Translational Medicine. 14: e1609. PMID 38488463 DOI: 10.1002/ctm2.1609 |
0.12 |
|
2024 |
Fogel EL, Easler JJ, Yuan Y, Yadav D, Conwell DL, Vege SS, Han SY, Park W, Patrick V, White FA. Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis: Protocol for a Phase 1 Clinical Trial to Determine Safety and Identify Side Effects. Jmir Research Protocols. 13: e50513. PMID 38451604 DOI: 10.2196/50513 |
0.12 |
|
2024 |
Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics. 80. PMID 38364811 DOI: 10.1093/biomtc/ujad022 |
0.12 |
|
2024 |
Kou B, Yu T, Tang J, Zhu X, Yuan Y, Tan W. Kitchen compost-derived humic acid application promotes ryegrass growth and enhances the accumulation of Cd: An analysis of the soil microenvironment and rhizosphere functional microbes. The Science of the Total Environment. 919: 170879. PMID 38354798 DOI: 10.1016/j.scitotenv.2024.170879 |
0.12 |
|
2015 |
Huang Q, Zheng S, Yang J, Yuan Y. [Formation mechanism of circulating tumor cells and progress of its application in I(-III( stage colorectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery. 18: 848-50. PMID 26303698 |
0.12 |
|
2023 |
Ding Y, Weng S, Zhu N, Mi M, Xu Z, Zhong L, Yuan Y. Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer. Heliyon. 9: e22092. PMID 38058653 DOI: 10.1016/j.heliyon.2023.e22092 |
0.119 |
|
2015 |
Huang Y, Li Q, Ge W, Hu Y, Cai S, Yuan Y, Zhang S, Zheng S. Optimizing sampling device for the fecal immunochemical test increases colonoscopy yields in colorectal cancer screening. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). PMID 25768975 DOI: 10.1097/CEJ.0000000000000154 |
0.119 |
|
2013 |
Yu Z, Yu JK, Fang XF, Yuan Y, Shen H. Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform. Hepato-Gastroenterology. 60: 1800-4. PMID 24624447 |
0.119 |
|
2016 |
Yao Y, Yu C, Yuan Y, Huang G, Li S. Median effective concentration of remifentanil in target controlled infusion for smooth tracheal extubation during emergence from general anesthesia in elderly patients Journal of Clinical Anesthesia. 31: 13-18. DOI: 10.1016/j.jclinane.2015.12.046 |
0.118 |
|
2020 |
Lin B, Wu J, Wang Y, Sun S, Yuan Y, Tao X, Lv R. Peptide functionalized upconversion/NIR II luminescent nanoparticles for targeted imaging and therapy of oral squamous cell carcinoma. Biomaterials Science. PMID 33305773 DOI: 10.1039/d0bm01737j |
0.118 |
|
2017 |
Zhu L, Huang Y, Fang X, Liu C, Deng W, Zhong C, Xu J, Xu D, Yuan Y. A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing. The Journal of Molecular Diagnostics : Jmd. PMID 29277635 DOI: 10.1016/j.jmoldx.2017.11.007 |
0.117 |
|
2022 |
Yuan Y, Diao S, Ni X, Zhang D, Yi W, Jian C, Hu X, Li D, Yu A, Zhou W, Fan Q. Peptide-based semiconducting polymer nanoparticles for osteosarcoma-targeted NIR-II fluorescence/NIR-I photoacoustic dual-model imaging and photothermal/photodynamic therapies. Journal of Nanobiotechnology. 20: 44. PMID 35062957 DOI: 10.1186/s12951-022-01249-4 |
0.116 |
|
2016 |
Zheng Y, Liang W, Yuan Y, Xiong C, Xie S, Wang H, Chai Y, Yuan R. Wavelength-resolved simultaneous photoelectrochemical bifunctional sensor on single interface: A newly in vitro approach for multiplexed DNA monitoring in cancer cells. Biosensors & Bioelectronics. 81: 423-430. PMID 27003607 DOI: 10.1016/j.bios.2016.03.032 |
0.116 |
|
2021 |
Zhao YX, Hu XY, Zhong X, Shen H, Yuan Y. High-intensity Focused Ultrasound Treatment as An Alternative Regimen for Myxofibrosarcoma. Dermatologic Therapy. e14816. PMID 33497505 DOI: 10.1111/dth.14816 |
0.116 |
|
2012 |
Yuan Y, Zhu H, Lin W, Marron JS. Local Polynomial Regression for Symmetric Positive Definite Matrices. Journal of the Royal Statistical Society. Series B, Statistical Methodology. 74: 697-719. PMID 23008683 DOI: 10.1111/J.1467-9868.2011.01022.X |
0.115 |
|
2023 |
Wang L, Han Y, Li L, Li X, Yuan Y. Clinical Efficacy Analysis of Functional Rhinoplasty Assisted by Nasal Endoscopy. Ear, Nose, & Throat Journal. 1455613231194133. PMID 37596873 DOI: 10.1177/01455613231194133 |
0.115 |
|
2022 |
Zhu N, Hu H, Yuan Y. Circulating tumor DNA analysis: potential to revise adjuvant therapy for stage II colorectal cancer. Signal Transduction and Targeted Therapy. 7: 308. PMID 36064813 DOI: 10.1038/s41392-022-01164-y |
0.115 |
|
2021 |
Zhu L, Li X, Yuan Y, Dong C, Yang M. Promoter Methylation in Gastrointestinal Cancer. Frontiers in Oncology. 11: 653222. PMID 33968756 DOI: 10.3389/fonc.2021.653222 |
0.114 |
|
2012 |
Yuan Y, Tan C, Li M, Shen H, Fang X, Hu Y, Ma S. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. World Journal of Surgical Oncology. 10: 235. PMID 23134665 DOI: 10.1186/1477-7819-10-235 |
0.114 |
|
2024 |
Li TT, Zhang PP, Zhang MC, Zhang H, Wang HY, Yuan Y, Wu SL, Wang XW, Sun ZG. Meta-analysis and systematic review of the relationship between sex and the risk or incidence of poststroke aphasia and its types. Bmc Geriatrics. 24: 220. PMID 38438862 DOI: 10.1186/s12877-024-04765-0 |
0.113 |
|
2022 |
Liu Y, Yuan Y, Day AJ, Zhang W, John P, Ng DJ, Banov D. Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause (New York, N.Y.). 29: 465-482. PMID 35357369 DOI: 10.1097/GME.0000000000001937 |
0.113 |
|
2020 |
Hu H, Liu X, Cai W, Wu D, Xu J, Yuan Y. A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program. Frontiers in Oncology. 10: 522. PMID 32391263 DOI: 10.3389/fonc.2020.00522 |
0.113 |
|
2019 |
Zhong C, Yu J, Li D, Jiang K, Tang Y, Yang M, Shen H, Fang X, Ding K, Zheng S, Yuan Y. Zyxin as a potential cancer prognostic marker promotes the proliferation and metastasis of colorectal cancer cells. Journal of Cellular Physiology. PMID 30697742 DOI: 10.1002/jcp.28236 |
0.113 |
|
2022 |
Ma Y, Wang Y, Hui X, Lin B, Yuan Y, Tao X, Lv R. Dual-molecular targeted NIR II probe with enhanced response for head and neck squamous cell carcinoma imaging. Nanotechnology. PMID 35189605 DOI: 10.1088/1361-6528/ac56f9 |
0.113 |
|
2012 |
Li XF, Li MD, Shen H, Fang XF, Huang PT, Yuan Y. Evaluation of therapeutic effect of tumor-targeted therapy. Oncotargets and Therapy. 5: 191-8. PMID 23049263 DOI: 10.2147/OTT.S36307 |
0.112 |
|
2019 |
Hu X, Shi G, Liu H, Jiang X, Deng J, Zhu C, Yuan Y, Ke B. Microbial contamination of rigid gas permeable (RGP) trial lenses and lens cases in China. Current Eye Research. PMID 31697186 DOI: 10.1080/02713683.2019.1687726 |
0.112 |
|
2013 |
Yuan Y, Gilmore JH, Geng X, Styner MA, Chen K, Wang JL, Zhu H. A longitudinal functional analysis framework for analysis of white matter tract statistics. Information Processing in Medical Imaging : Proceedings of the ... Conference. 23: 220-31. PMID 24683971 DOI: 10.1007/978-3-642-38868-2_19 |
0.112 |
|
2016 |
Zhu W, Yuan Y, Zhang J, Zhou F, Knickmeyer RC, Zhu H. Genome-wide Association Analysis of Secondary Imaging Phenotypes from the Alzheimer's Disease Neuroimaging Initiative Study. Neuroimage. PMID 27717770 DOI: 10.1016/J.Neuroimage.2016.09.055 |
0.112 |
|
2019 |
Yuan Y, Ma Z, Wang F. Leveraging local MP2 to reduce basis set superposition errors: An efficient first-principles based force-field for carbon dioxide. The Journal of Chemical Physics. 151: 184501. PMID 31731863 DOI: 10.1063/1.5124811 |
0.112 |
|
2023 |
Luo L, Yin J, Li Z, Zhang W, Yuan Y, Tang Y, Deng Y, Zhu L. Bilateral tonic seizures probably induced by eperisone hydrochloride: a case report. Frontiers in Neurology. 14: 1240526. PMID 37780713 DOI: 10.3389/fneur.2023.1240526 |
0.111 |
|
2022 |
Ding X, Liu H, Yuan Y, Zhong Q, Zhong X. Roles of GFPT2 Expression Levels on the Prognosis and Tumor Microenvironment of Colon Cancer. Frontiers in Oncology. 12: 811559. PMID 35330716 DOI: 10.3389/fonc.2022.811559 |
0.111 |
|
2021 |
Wu J, Liu J, Lin B, Lv R, Yuan Y, Tao X. Met-Targeted Dual-Modal MRI/NIR II Imaging for Specific Recognition of Head and Neck Squamous Cell Carcinoma. Acs Biomaterials Science & Engineering. PMID 33719394 DOI: 10.1021/acsbiomaterials.0c01807 |
0.111 |
|
2021 |
Carmack CL, Parker NH, Demark-Wahnefried W, Shely L, Baum G, Yuan Y, Giordano SH, Rodriguez-Bigas M, Pettaway C, Basen-Engquist K. Healthy Moves to Improve Lifestyle Behaviors of Cancer Survivors and Their Spouses: Feasibility and Preliminary Results of Intervention Efficacy. Nutrients. 13. PMID 34960013 DOI: 10.3390/nu13124460 |
0.111 |
|
2020 |
Feng M, Wang Y, Lin B, Peng X, Yuan Y, Tao X, Lv R. Degradable pH-responsive NIR-II imaging probes based on a polymer-lanthanide composite for chemotherapy. Dalton Transactions (Cambridge, England : 2003). PMID 32597918 DOI: 10.1039/d0dt02042g |
0.11 |
|
2023 |
Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, ... Yuan Y, et al. Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer Research Communications. PMID 38126764 DOI: 10.1158/2767-9764.CRC-22-0260 |
0.11 |
|
2021 |
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, et al. Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34187851 DOI: 10.1158/1078-0432.CCR-21-0585 |
0.11 |
|
2016 |
Zhang H, Zhang L, Wei L, Gao X, Tang L, Gong W, Min N, Yuan Y. Knockdown of cathepsin L sensitizes ovarian cancer cells to chemotherapy Oncology Letters. 11: 4235-4239. DOI: 10.3892/ol.2016.4494 |
0.11 |
|
2017 |
Li XF, Tan YN, Zhong CH, Zhu LZ, Fang XF, Li J, Ding KF, Yuan Y. Left-sided primary tumor is a favorable prognostic factor for metastatic colorectal cancer patients receiving surgery. Oncotarget. 8: 79618-79628. PMID 29108341 DOI: 10.18632/oncotarget.18896 |
0.11 |
|
2017 |
Li XF, Tan YN, Zhong CH, Zhu LZ, Fang XF, Li J, Ding KF, Yuan Y. Left-sided primary tumor is a favorable prognostic factor for metastatic colorectal cancer patients receiving surgery. Oncotarget. PMID 28699900 DOI: 10.18632/oncotarget.18896 |
0.11 |
|
2020 |
Cheng Y, Fang XF, Hu HG, Wang J, Sun LF, Yuan Y. Successful treatment of metastatic colorectal cancer with synchronous mutation and dMMR with BGB-A317. Immunotherapy. PMID 32172642 DOI: 10.2217/imt-2019-0148 |
0.109 |
|
2023 |
Yuan Y, Diao S, Zhang D, Yi W, Qi B, Hu X, Xie C, Fan Q, Yu A. A targeted activatable NIR-II nanoprobe for positive visualization of anastomotic thrombosis and sensitive identification of fresh fibrinolytic thrombus. Materials Today. Bio. 21: 100697. PMID 37346779 DOI: 10.1016/j.mtbio.2023.100697 |
0.109 |
|
2016 |
Yang L, Yuan Y, Fu C, Xu X, Zhou J, Wang S, Kong L, Li Z, Guo Q, Wei L. LZ-106, a novel analogue of enoxacin, inducing apoptosis via activation of ROS-dependent DNA damage response in NSCLCs. Free Radical Biology & Medicine. PMID 27012423 DOI: 10.1016/j.freeradbiomed.2016.03.007 |
0.109 |
|
2018 |
Wilson Dib R, Chaftari AM, Hachem RY, Yuan Y, Dandachi D, Raad II. Catheter-Related Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy. Open Forum Infectious Diseases. 5: ofy249. PMID 30377625 DOI: 10.1093/ofid/ofy249 |
0.109 |
|
2023 |
Yang M, Xu Z, Mi M, Ding Y, Pan Y, Yuan Y, Sun W, Weng S. CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice. Cancer Biology & Medicine. PMID 37700433 DOI: 10.20892/j.issn.2095-3941.2023.0211 |
0.109 |
|
2014 |
Ma L, Zhang S, Yuan Y, Gao J. Hypouricemic actions of exopolysaccharide produced by Cordyceps militaris in potassium oxonate-induced hyperuricemic mice. Current Microbiology. 69: 852-7. PMID 25086583 DOI: 10.1007/s00284-014-0666-9 |
0.109 |
|
2015 |
Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, Zhu LZ, Fang XF, Yuan Y. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World Journal of Gastroenterology : Wjg. 21: 6470-6478. PMID 26074686 DOI: 10.3748/wjg.v21.i21.6470 |
0.108 |
|
2020 |
Xiao Q, Lu W, Kong X, Shao YW, Hu Y, Wang A, Bao H, Cao R, Liu K, Wang X, Wu X, Zheng S, Yuan Y, Ding K. Alterations of circulating bacterial DNA in colorectal cancer and adenoma: A proof-of-concept study. Cancer Letters. PMID 33249197 DOI: 10.1016/j.canlet.2020.11.030 |
0.108 |
|
2021 |
Zhao J, Shen H, Hu X, Wang Y, Yuan Y. The efficacy of a new high-intensity focused ultrasound therapy for metastatic pancreatic cancer. International Journal of Hyperthermia : the Official Journal of European Society For Hyperthermic Oncology, North American Hyperthermia Group. 38: 288-295. PMID 33615955 DOI: 10.1080/02656736.2021.1876252 |
0.108 |
|
2020 |
Tan Y, Hu Y, Xiao Q, Tang Y, Chen H, He J, Chen L, Jiang K, Wang Z, Yuan Y, Ding K. Silencing of brain-expressed X-linked 2 (BEX2) promotes colorectal cancer metastasis through the Hedgehog signaling pathway. International Journal of Biological Sciences. 16: 228-238. PMID 31929751 DOI: 10.7150/ijbs.38431 |
0.108 |
|
2018 |
Li X, Li X, Fang X, Yuan Y. Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. Oncotargets and Therapy. 11: 4047-4050. PMID 30038504 DOI: 10.2147/OTT.S154567 |
0.107 |
|
2023 |
Jiang L, Du X, Pan Z, Yuan Y, Wang Y. Lumbar disc herniation in juveniles: a case control study of MRI characteristics and etiological insights. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. PMID 37165707 DOI: 10.1002/jor.25598 |
0.107 |
|
2021 |
Wang L, Yuan Y, Yu X, Han Y, Yue J, Li L, Liu W. [Analysis of clinical characteristics of fungal ball in unilateral maxillary sinus]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery. 35: 328-332. PMID 33794631 DOI: 10.13201/j.issn.2096-7993.2021.04.010 |
0.107 |
|
2013 |
Yuan Y, Shen H, Hu H, Ye X, Zhong X. Solitary pulmonary mass in a patient with a history of lymphoma: a case report. Journal of Medical Case Reports. 7: 113. PMID 23618014 DOI: 10.1186/1752-1947-7-113 |
0.107 |
|
2021 |
Qi L, Chen J, Zhou B, Xu K, Wang K, Fang Z, Shao Y, Yuan Y, Zheng S, Hu W. HomeoboxC6 promotes metastasis by orchestrating the DKK1/Wnt/β-catenin axis in right-sided colon cancer. Cell Death & Disease. 12: 337. PMID 33795652 DOI: 10.1038/s41419-021-03630-x |
0.107 |
|
2019 |
Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, ... ... Yuan Y, et al. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Translational Lung Cancer Research. 8: 989-999. PMID 32010577 DOI: 10.21037/tlcr.2019.12.23 |
0.107 |
|
2007 |
Yuan Y, Cao WM, Cai SR, Zhang SZ. [Clinical phenotype of Chinese hereditary nonpolyposis colorectal cancer (HNPCC) families]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 28: 36-8. PMID 16737618 |
0.107 |
|
2014 |
Li J, Liu Y, Wang JW, Gao Y, Hu YT, He JJ, Yu XY, Hu HG, Yuan Y, Zhang SZ, Ding KF. Oxaliplatin-based adjuvant chemotherapy without radiotherapy can improve the survival of locally-advanced rectal cancer. Plos One. 9: e107872. PMID 25243406 DOI: 10.1371/journal.pone.0107872 |
0.106 |
|
2004 |
Yuan Y, Ye J, Zheng S. Clinical and genetic features of International Collaborative Group-hereditary nonpolyposis colorectal cancer families and suspected hereditary nonpolyposis colorectal cancer families. Chinese Medical Journal. 117: 748-52. PMID 15161546 |
0.106 |
|
2023 |
Wang Y, Li W, Lin B, Yuan Y, Ning P, Tao X, Lv R. NIR-II imaging-guided photothermal cancer therapy combined with enhanced immunogenic death. Biomaterials Science. PMID 37334508 DOI: 10.1039/d3bm00700f |
0.106 |
|
2019 |
Yu L, Wang L, Tan Y, Hu H, Shen L, Zheng S, Ding K, Zhang S, Yuan Y. Accuracy of Magnetic Resonance Imaging in Staging Rectal Cancer with Multidisciplinary Team: A Single-Center Experience. Journal of Cancer. 10: 6594-6598. PMID 31777588 DOI: 10.7150/jca.32685 |
0.106 |
|
2022 |
Wang N, Wang H, Jiang H, Bi Y, Zhao Y, He X, Cao F, Yuan Y. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report. Annals of Palliative Medicine. 11: 1147-1152. PMID 35365045 DOI: 10.21037/apm-22-168 |
0.106 |
|
2022 |
Weng S, Zhang D, Yang M, Wang L, Yuan Y. Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review. Zeitschrift Fur Gastroenterologie. PMID 35584781 DOI: 10.1055/a-1826-2814 |
0.106 |
|
2022 |
Aisa A, Tan Y, Li X, Zhang D, Shi Y, Yuan Y. Comprehensive Analysis of the Brain-Expressed X-Link Protein Family in Glioblastoma Multiforme. Frontiers in Oncology. 12: 911942. PMID 35860560 DOI: 10.3389/fonc.2022.911942 |
0.105 |
|
2018 |
Yu J, Huang Y, Lin C, Li X, Fang X, Zhong C, Yuan Y, Zheng S. Identification of Kininogen 1 as a Serum Protein Marker of Colorectal Adenoma in Patients with a Family History of Colorectal Cancer. Journal of Cancer. 9: 540-547. PMID 29535795 DOI: 10.7150/jca.22405 |
0.105 |
|
2018 |
Kong X, Li J, Cai Y, Tian Y, Chi S, Tong D, Hu Y, Yang Q, Li J, Poston G, Yuan Y, Ding K. A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database. Bmc Cancer. 18: 50. PMID 29310604 DOI: 10.1186/S12885-017-3796-1 |
0.105 |
|
2013 |
Yuan Y, Zhu H, Styner M, Gilmore JH, Marron JS. VARYING COEFFICIENT MODEL FOR MODELING DIFFUSION TENSORS ALONG WHITE MATTER TRACTS. The Annals of Applied Statistics. 7: 102-125. PMID 24533040 DOI: 10.1214/12-Aoas574 |
0.105 |
|
2019 |
Yuan Y, Wang X, Xu X, Liu Y, Li C, Yang M, Yang Y, Ma Z. Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. Acs Infectious Diseases. PMID 31849218 DOI: 10.1021/acsinfecdis.9b00374 |
0.105 |
|
2009 |
Yang Y, Su Y, Sun J, Lai X, Wang K, Jiang S, Zhang J, Yuan Y, Sheng J. Kinetics of Formation and Evolution of Phase Structure in Multipolymer: 1. The Application of Semilogarithmic Plot Method to Early Stage of Phase Dispersion Journal of Macromolecular Science, Part B. 48: 1042-1058. DOI: 10.1080/00222340903038661 |
0.104 |
|
2022 |
Zhang L, Zhuang W, Yuan Y, Shen J, Shi W, Liu G, Wu W, Zhang Q, Shao G, Mei Q, Fan Q. Novel Glutathione Activated Smart Probe for Photoacoustic Imaging, Photothermal Therapy, and Safe Postsurgery Treatment. Acs Applied Materials & Interfaces. PMID 35604134 DOI: 10.1021/acsami.2c04470 |
0.104 |
|
2021 |
Hu Y, Fang Z, Mu J, Huang Y, Zheng S, Yuan Y, Guo C. Quantitative Analysis of Methylated Adenosine Modifications Revealed Increased Levels of -Methyladenosine (mA) and ,2'--Dimethyladenosine (mAm) in Serum From Colorectal Cancer and Gastric Cancer Patients. Frontiers in Cell and Developmental Biology. 9: 694673. PMID 34381776 DOI: 10.3389/fcell.2021.694673 |
0.103 |
|
2014 |
Yan J, Yuan Y, Mu R, Shang H, Guan Y. LNA-modified isothermal oligonucleotide microarray for differentiating bacilli of similar origin. Journal of Biosciences. 39: 795-804. PMID 25431409 |
0.103 |
|
2023 |
Li X, Chen J, Aisa A, Ding Y, Zhang D, Yuan Y. Targeting BRCA-Mutant Biliary Tract Cancer: Current Evidences and Future Perspectives. Journal of Digestive Diseases. PMID 36987380 DOI: 10.1111/1751-2980.13168 |
0.102 |
|
2023 |
Yang N, Yuan Y, Zhang C, Liu X, Wang X, Li Y. Accurate characterization of full-chain infrared multispectral imaging features under an aerodynamic thermal environment. Optics Express. 31: 26643-26658. PMID 37710520 DOI: 10.1364/OE.494011 |
0.102 |
|
2020 |
Yuan Y, Qian XL, Yan WM, Zhou S. [Fire needling on dysphagia due to pseudobulbar palsy after stroke: a randomized controlled trial]. Zhongguo Zhen Jiu = Chinese Acupuncture & Moxibustion. 40: 347-51. PMID 32275359 DOI: 10.13703/j.0255-2930.20190502-0003 |
0.102 |
|
2017 |
Guo C, Li X, Ye M, Xu F, Yu J, Xie C, Cao X, Guo M, Yuan Y, Zheng S. Discriminating patients with early-stage breast cancer from benign lesions by detection of oxidative DNA damage biomarker in urine. Oncotarget. 8: 53100-53109. PMID 28881796 DOI: 10.18632/oncotarget.17831 |
0.101 |
|
2017 |
Guo C, Li X, Ye M, Xu F, Yu J, Xie C, Cao X, Guo M, Yuan Y, Zheng S. Discriminating patients with early-stage breast cancer from benign lesions by detection of oxidative DNA damage biomarker in urine. Oncotarget. PMID 28562355 DOI: 10.18632/oncotarget.17831 |
0.101 |
|
2021 |
Yao D, Yu L, He W, Hu Y, Xu H, Yuan Y, Dai H. Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015-2019: an observational retrospective database analysis. Bmj Open. 11: e046166. PMID 34706945 DOI: 10.1136/bmjopen-2020-046166 |
0.101 |
|
2021 |
Bai R, Wu D, Shi Z, Hu W, Li J, Chen Y, Ge W, Yuan Y, Zheng S. Pan-cancer analyses demonstrate that ANKRD6 is associated with a poor prognosis and correlates with M2 macrophage infiltration in colon cancer. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 33: 93-102. PMID 33707932 DOI: 10.21147/j.issn.1000-9604.2021.01.10 |
0.101 |
|
2006 |
Wang XL, Yuan Y, Zhang SZ, Cai SR, Huang YQ, Jiang Q, Zheng S. Clinical and genetic characteristics of Chinese hereditary nonpolyposis colorectal cancer families. World Journal of Gastroenterology. 12: 4074-7. PMID 16810763 DOI: 10.3748/wjg.v12.i25.4074 |
0.1 |
|
2017 |
Yu J, Zhai X, Li X, Zhong C, Guo C, Yang F, Yuan Y, Zheng S. Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Scientific Reports. 7: 14265. PMID 29079854 DOI: 10.1038/s41598-017-14539-x |
0.1 |
|
2016 |
Yuan Y, Wang J, Wu Y, Li G, Tao X. Prognostic value of computed tomography characteristics for overall survival in patients with maxillary cancer. Bmc Cancer. 16: 783. PMID 27724942 DOI: 10.1186/S12885-016-2830-Z |
0.1 |
|
2017 |
Yuan Y, Zhang H, Liu X, Lu Z, Li G, Lu M, Tao X. MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the Cancer Genome Atlas. Oncotarget. 8: 58386-58393. PMID 28938564 DOI: 10.18632/Oncotarget.16878 |
0.1 |
|
2017 |
Yuan Y, Zhang H, Liu X, Lu Z, Li G, Lu M, Tao X. MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the cancer genome atlas. Oncotarget. PMID 28430657 DOI: 10.18632/oncotarget.16878 |
0.1 |
|
2012 |
Han X, Fang X, Lou X, Hua D, Ding W, Foltz G, Hood L, Yuan Y, Lin B. Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. Plos One. 7: e41335. PMID 22912670 DOI: 10.1371/Journal.Pone.0041335 |
0.1 |
|
2011 |
Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y, Zheng S. SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World Journal of Gastroenterology. 17: 2028-36. PMID 21528083 DOI: 10.3748/wjg.v17.i15.2028 |
0.099 |
|
2021 |
Yuan Y, Wang F. A comparison of three DFT exchange-correlation functionals and two basis sets for the prediction of the conformation distribution of hydrated polyglycine. The Journal of Chemical Physics. 155: 094104. PMID 34496578 DOI: 10.1063/5.0059669 |
0.099 |
|
2016 |
Ding J, Deng M, Song XC, Chen C, Lai KL, Wang GS, Yuan YY, Xu T, Zhu L. Nanofibrous biomimetic mesh can be used for pelvic reconstructive surgery: A randomized study. Journal of the Mechanical Behavior of Biomedical Materials. 61: 26-35. PMID 26820994 DOI: 10.1016/J.Jmbbm.2016.01.003 |
0.099 |
|
2009 |
Shen H, Yuan Y, Song YM, Huang YQ, Zheng S. [Comparison of clinical and genetic phenotypes between Chinese and Korean hereditary nonpolyposis colorectal cancer families]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics. 25: 326-30. PMID 18543228 |
0.099 |
|
2024 |
Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, et al. Limited Independent Follow-Up with Germline Testing of Variants Detected in and by Tumor-Only Sequencing. Journal of Immunotherapy and Precision Oncology. 7: 7-17. PMID 38327755 DOI: 10.36401/JIPO-23-2 |
0.098 |
|
2021 |
Yuan Y, Yuan HF, Geng Y, Zhao LN, Yun HL, Wang YF, Yang G, Zhang XD. Aspirin modulates 2-hydroxyisobutyrylation of ENO1K281 to attenuate the glycolysis and proliferation of hepatoma cells. Biochemical and Biophysical Research Communications. 560: 172-178. PMID 34000466 DOI: 10.1016/j.bbrc.2021.04.083 |
0.098 |
|
2024 |
Dasgupta P, Ou A, Lin H, Gregory T, Alfaro-Munoz KD, Yuan Y, Afshar-Khargan V, Kamiya-Matsuoka C, Rousseau JF, Majd NK. The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. Journal of Neuro-Oncology. PMID 38372903 DOI: 10.1007/s11060-023-04551-9 |
0.098 |
|
2023 |
Cao X, Wang M, Huang Y, Zhang M, Zheng F, Zhang G, Su J, Yuan Y, Guo C. Determination of dimethylated nucleosides in serum from colorectal cancer patients by hydrophilic interaction liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1232: 123973. PMID 38142502 DOI: 10.1016/j.jchromb.2023.123973 |
0.098 |
|
2010 |
Yuan Y, Chen XS, Liu SY, Shen KW. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. Ajr. American Journal of Roentgenology. 195: 260-8. PMID 20566826 DOI: 10.2214/AJR.09.3908 |
0.098 |
|
2018 |
Vidrine DJ, Frank-Pearce SG, Vidrine JI, Tahay PD, Marani SK, Chen S, Yuan Y, Cantor SB, Prokhorov AV. Efficacy of Mobile Phone-Delivered Smoking Cessation Interventions for Socioeconomically Disadvantaged Individuals: A Randomized Clinical Trial. Jama Internal Medicine. PMID 30556832 DOI: 10.1001/jamainternmed.2018.5713 |
0.097 |
|
2016 |
Zhao Y, Bi Q, Yuan Y, Lv H. Void fraction measurement in steam-water two-phase flow using the gamma ray attenuation under high pressure and high temperature evaporating conditions Flow Measurement and Instrumentation. 49: 18-30. DOI: 10.1016/J.Flowmeasinst.2016.03.002 |
0.097 |
|
2023 |
Yang G, Xiao Z, Ren J, Xia R, Wu Y, Yuan Y, Tao X. Machine learning based on magnetic resonance imaging and clinical parameters helps predict mesenchymal-epithelial transition factor expression in oral tongue squamous cell carcinoma: a pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. PMID 38246808 DOI: 10.1016/j.oooo.2023.12.789 |
0.097 |
|
2013 |
Fang XF, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, Li XF, Yu LK, Yuan Y. Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World Journal of Gastroenterology : Wjg. 19: 2331-9. PMID 23613626 DOI: 10.3748/wjg.v19.i15.2331 |
0.097 |
|
2012 |
Fang WJ, Zheng Y, Wu LM, Ke QH, Shen H, Yuan Y, Zheng SS. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pacific Journal of Cancer Prevention : Apjcp. 13: 1917-21. PMID 22901147 DOI: 10.7314/APJCP.2012.13.5.1917 |
0.097 |
|
2022 |
Zheng D, Yuan Y, Wang F. Fragmentation Method for Computing Quantum Mechanics and Molecular Mechanics Gradients for Force Matching: Validation with Hydration Free Energy Predictions Using Adaptive Force Matching. The Journal of Physical Chemistry. A. PMID 35420821 DOI: 10.1021/acs.jpca.2c01615 |
0.096 |
|
2023 |
Yuan Z, Yang M, Yuan Y. The Progress of Colorectal Polyposis Syndrome in Chinese Population. Clinics in Colon and Rectal Surgery. 36: 391-399. PMID 37795462 DOI: 10.1055/s-0043-1767708 |
0.096 |
|
2016 |
Li J, Yi CH, Hu YT, Li JS, Yuan Y, Zhang SZ, Zheng S, Ding KF. TNM Staging of Colorectal Cancer Should be Reconsidered According to Weighting of the T Stage: Verification Based on a 25-Year Follow-Up. Medicine. 95: e2711. PMID 26871810 DOI: 10.1097/MD.0000000000002711 |
0.096 |
|
2023 |
Zhao Z, Yuan Y, Zhang C, Wang X, Gao W. Imaging quality characterization and optimization of segmented planar imaging system based on honeycomb dense azimuth sampling lens array. Optics Express. 31: 35670-35684. PMID 38017733 DOI: 10.1364/OE.499456 |
0.096 |
|
2023 |
Zou Y, Li D, Yu X, Zhou C, Zhu C, Yuan Y. Correlation of Neuroendocrine Differentiation with A Distinctively Suppressive Immune Microenvironment in Gastric Cancer. Neuroendocrinology. PMID 37827134 DOI: 10.1159/000534427 |
0.096 |
|
2016 |
Zhu L, Li X, Shen Y, Cao Y, Fang X, Chen J, Yuan Y. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Oncotargets and Therapy. 9: 4879-86. PMID 27540301 DOI: 10.2147/OTT.S107279 |
0.096 |
|
2016 |
Chen QX, Yuan Y, Shuai Y, Tan HP. Graphical aerosol classification method using aerosol relative optical depth Atmospheric Environment. 135: 84-91. DOI: 10.1016/j.atmosenv.2016.03.061 |
0.096 |
|
2006 |
Zhou J, Yuan Y, Reynolds R, Raber S, Li Y. Cost-efficient higher-order crossover designs in comparative bioavailability studies. Clinical Pharmacokinetics. 45: 623-32. PMID 16719543 DOI: 10.2165/00003088-200645060-00005 |
0.096 |
|
2021 |
Gao W, Yuan Y, Wang X, Ma L, Zhao Z, Yuan H. Quantitative analysis and optimization design of the segmented planar integrated optical imaging system based on an inhomogeneous multistage sampling lens array. Optics Express. 29: 11869-11884. PMID 33984959 DOI: 10.1364/OE.421298 |
0.095 |
|
2022 |
Zhong X, Hu X, Zhao P, Wang Y, Fang XF, Shen J, Shen H, Yuan Y. The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor. Cancer Medicine. PMID 35274811 DOI: 10.1002/cam4.4573 |
0.095 |
|
2023 |
Yuan Y, Zheng L, Rong J, Zhao X, Wu G, Zhuang Z. Revealing the crystal phase-activity relationship on NiRu alloy nanoparticles encapsulated in N-doped carbon towards efficient hydrogen evolution reaction. Chemistry (Weinheim An Der Bergstrasse, Germany). e202300062. PMID 36806259 DOI: 10.1002/chem.202300062 |
0.095 |
|
2021 |
Zhu Y, Dai H, Wang Y, Liang Y, Feng W, Yuan Y. Targeting FEN1 Suppresses the Proliferation of Chronic Myeloid Leukemia Cells Through Regulating Alternative End-Joining Pathways. Dna and Cell Biology. PMID 34156283 DOI: 10.1089/dna.2021.0239 |
0.095 |
|
2022 |
Yuan Y, Zhang W, Liu C, He Y, Zhang H, Xu L, Yang B, Zhao Y, Ma Y, Chu M, Zhao Z, Huang Y, Han Y, Zeng Y, Ren H, et al. Genome-Wide Selective Analysis of Boer Goat to Investigate the Dynamic Heredity Evolution under Different Stages. Animals : An Open Access Journal From Mdpi. 12. PMID 35681821 DOI: 10.3390/ani12111356 |
0.095 |
|
2023 |
Mi M, Weng S, Xu Z, Hu H, Wang Y, Yuan Y. CSCO guidelines for colorectal cancer version 2023: Updates and insights. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 35: 233-238. PMID 37440826 DOI: 10.21147/j.issn.1000-9604.2023.03.02 |
0.095 |
|
2023 |
Xiang Y, Yuan Y, Liu J, Xu X, Wang Z, Hassan S, Wu Y, Sun Q, Shen Y, Wang L, Yang H, Sun J, Xu G, Huang Q. A nomogram based on clinical factors to predict calendar year readmission in patients with ulcerative colitis. Therapeutic Advances in Gastroenterology. 16: 17562848231189124. PMID 37533706 DOI: 10.1177/17562848231189124 |
0.094 |
|
2019 |
Yuan Y, Wang J, Wu D, Zhang D, Song W. Effect of Transcutaneous Vagus Nerve Stimulation in Dysphagia After Lateral Medullary Infarction: A Case Report. American Journal of Speech-Language Pathology. 1-7. PMID 31498703 DOI: 10.1044/2019_AJSLP-18-0262 |
0.094 |
|
2020 |
Chen Q, Hu Y, Fang Z, Ye M, Li J, Zhang S, Yuan Y, Guo C. Elevated Levels of Oxidative Nucleic Acid Modification Markers in Urine From Gastric Cancer Patients: Quantitative Analysis by Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry. Frontiers in Chemistry. 8: 606495. PMID 33392149 DOI: 10.3389/fchem.2020.606495 |
0.094 |
|
2015 |
Tan Y, Fu J, Li X, Yang J, Jiang M, Ding K, Xu J, Li J, Yuan Y. A minor (<50%) signet-ring cell component associated with poor prognosis in colorectal cancer patients: a 26-year retrospective study in China. Plos One. 10: e0121944. PMID 25789685 DOI: 10.1371/journal.pone.0121944 |
0.094 |
|
2019 |
Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z, Zheng S, Wan D, He J, Wang J, Ba Y, Bai C, Bai L, Bai W, Bi F, et al. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). Journal of Hematology & Oncology. 12: 16. PMID 30764882 DOI: 10.1186/S13045-019-0702-0 |
0.093 |
|
2022 |
Ma Z, He S, Yuan Y, Zhuang Z, Liu Y, Wang H, Chen J, Xu X, Ding C, Molodtsov V, Lin W, Robertson GT, Weiss WJ, Pulse M, Nguyen P, et al. Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens. Journal of Medicinal Chemistry. PMID 35175750 DOI: 10.1021/acs.jmedchem.1c02045 |
0.093 |
|
2015 |
Sun R, Zhang J, Zhang F, Fan J, Yuan Y, Li C. Selectively predictive calcium supplementation using NCCN risk stratification system after thyroidectomy with differentiated thyroid cancer. International Journal of Clinical and Experimental Medicine. 8: 21939-46. PMID 26885165 |
0.093 |
|
2014 |
Yuan Y, Li XF, Chen JQ, Dong CX, Weng SS, Huang JJ. Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. Oncotargets and Therapy. 7: 841-52. PMID 24920926 DOI: 10.2147/OTT.S34124 |
0.093 |
|
2016 |
Sun S, Jiang Y, Yuan Y, Hu B, Yeo TS. Defocusing and distortion elimination for shipborne bistatic ISAR Remote Sensing Letters. 7: 523-532. DOI: 10.1080/2150704X.2016.1163746 |
0.092 |
|
2018 |
Liu X, Fang X, Hu H, Fu X, Chen Y, Yuan Y. Efficacy of vemurafenib in a heavy smoker with BRAF-mutated lung adenocarcinoma: A case report and literature review. Molecular and Clinical Oncology. 9: 472-476. PMID 30214735 DOI: 10.3892/mco.2018.1691 |
0.092 |
|
2021 |
Yang M, Li D, Jiang W, Zhu L, Ju H, Sun Y, Shan Y, Yang C, Dong J, Wang L, Wu B, Qiu M, Yin X, Wang X, Xiong B, ... ... Yuan Y, et al. Development and external validation of a novel nomogram for screening Chinese Lynch syndrome: based on a multicenter, population study. Therapeutic Advances in Medical Oncology. 13: 17588359211023290. PMID 34178123 DOI: 10.1177/17588359211023290 |
0.092 |
|
2021 |
Dong C, Ding Y, Weng S, Li G, Huang Y, Hu H, Zhang Z, Zhang S, Yuan Y. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 33: 302-307. PMID 34321827 DOI: 10.21147/j.issn.1000-9604.2021.03.02 |
0.092 |
|
2020 |
Weng S, Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X, Zhou A, Zhang Z, Li G, Cai S, Xu R, Li J, Zhang S. Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 32: 403-407. PMID 32694904 DOI: 10.21147/j.issn.1000-9604.2020.03.11 |
0.092 |
|
2019 |
Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X, Zhou A, Zhang Z, Li G, Cai S, Xu R, Li J, Zhang S. Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 31: 423-425. PMID 31354210 DOI: 10.21147/j.issn.1000-9604.2019.03.03 |
0.092 |
|
2024 |
Li Y, Lu S, Yao P, Huang W, Huang Y, Zhou Y, Yuan Y, Cheng S, Wu F. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report. Medicine. 103: e36992. PMID 38241569 DOI: 10.1097/MD.0000000000036992 |
0.092 |
|
2013 |
Xiang TX, Yuan Y, Li LL, Wang ZH, Dan LY, Chen Y, Ren GS, Tao Q. Aberrant promoter CpG methylation and its translational applications in breast cancer. Chinese Journal of Cancer. 32: 12-20. PMID 22059908 DOI: 10.5732/Cjc.011.10344 |
0.092 |
|
2016 |
Tan Y, Li X, Chen H, Hu Y, Jiang M, Fu J, Yuan Y, Ding K. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study. Oncotarget. PMID 27542240 DOI: 10.18632/oncotarget.11235 |
0.091 |
|
2019 |
Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, Alfred Yung WK. Wild-type defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. American Journal of Cancer Research. 9: 1734-1745. PMID 31497354 |
0.091 |
|
2024 |
Yuan Y, Chen B, Song L, An X, Zhang Q, Lu H, Li CM, Guo C. Magnetic two-dimensional nanocomposites for multimodal antitumor therapy: a recent review. Journal of Materials Chemistry. B. PMID 38251275 DOI: 10.1039/d3tb02333h |
0.091 |
|
2011 |
Shen H, Yuan Y, Hu HG, Zhong X, Ye XX, Li MD, Fang WJ, Zheng S. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World Journal of Gastroenterology. 17: 809-16. PMID 21390154 DOI: 10.3748/wjg.v17.i6.809 |
0.091 |
|
2016 |
Chen JQ, Kong YY, Weng SS, Dong CX, Zhu LZ, Yang Z, Zhong J, Yuan Y. Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database. Oncotarget. PMID 28008147 DOI: 10.18632/oncotarget.14027 |
0.091 |
|
Hide low-probability matches. |